<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006752.pub2" GROUP_ID="SCHIZ" ID="123706090110371416" MERGED_FROM="" MODIFIED="2012-10-17 20:38:39 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.9&lt;/p&gt;" NOTES_MODIFIED="2009-08-07 09:48:59 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2012-10-17 20:38:39 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Sertindole versus other atypical antipsychotics for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-10-17 20:38:39 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-10-17 20:38:39 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="87F1AFC682E26AA20078D4E6A8FF088C" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Katja</FIRST_NAME><LAST_NAME>Komossa</LAST_NAME><POSITION>4th Year Resident (Dr. Med)</POSITION><EMAIL_1>k.komossa@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychosomatische und Medizin und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München, Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Moehlstrasse 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049 (0) 89 4141/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="11852B3682E26AA201DC7B3E1C938991" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Christine</FIRST_NAME><LAST_NAME>Rummel-Kluge</LAST_NAME><POSITION>Fachärztin für Psychiatrie und Psychotherapie</POSITION><EMAIL_1>Christine.rummel-kluge@medizin.uni-leipzig.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Leipzig</DEPARTMENT><ORGANISATION/><ADDRESS_1>Semmelweisstr. 10</ADDRESS_1><CITY>04103 Leipzig</CITY><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-34-1972-4493</PHONE_1><FAX_1>+49-34-1972-4599</FAX_1></ADDRESS></PERSON><PERSON ID="2E84257C82E26AA201BA4B54250245B7" ROLE="AUTHOR"><FIRST_NAME>Heike</FIRST_NAME><LAST_NAME>Hunger</LAST_NAME><EMAIL_1>mailtoHeike@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+498 941 404247</PHONE_1></ADDRESS></PERSON><PERSON ID="90591E5482E26AA201AA8B42BEBB7D04" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Sandra</FIRST_NAME><LAST_NAME>Schwarz</LAST_NAME><EMAIL_1>sandra.schwarz@khsweb.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="D99E43AC82E26AA201BA4B549DE5F4E8" ROLE="AUTHOR"><FIRST_NAME>Franziska</FIRST_NAME><LAST_NAME>Schmid</LAST_NAME><EMAIL_1>supra.renin@web.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>0049/89/4140/4247</PHONE_1></ADDRESS></PERSON><PERSON ID="13477" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Ruth</FIRST_NAME><LAST_NAME>Lewis</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>lewisr17@Cardiff.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care and Public Health</DEPARTMENT><ORGANISATION>Cardiff University</ORGANISATION><ADDRESS_1>Centre for Health Sciences / North Wales Clinical School</ADDRESS_1><ADDRESS_2>School of Medicine, Gwenfro Building</ADDRESS_2><CITY>Wrexham</CITY><ZIP>LL13 7YP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)1978 727340</PHONE_1><FAX_1>+44 (0)1978 261258</FAX_1></ADDRESS></PERSON><PERSON ID="11850D1F82E26AA201DC7B3E2041CA58" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Werner</FIRST_NAME><LAST_NAME>Kissling</LAST_NAME><POSITION>Leitender Oberarzt</POSITION><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>49-89-4140-4207</PHONE_1><FAX_1>49-89-4140-4894</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Oberarzt</POSITION><EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Möhlstr. 26</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-08-07 09:44:51 +0100" MODIFIED_BY="Bethany York">
<UP_TO_DATE>
<DATE DAY="21" MONTH="8" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="8" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="8" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2012-10-17 20:38:39 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-17 20:38:39 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="17" MONTH="10" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2012-10-17 20:38:39 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-17 20:38:39 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="10" MONTH="11" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-11-10 15:36:24 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="11" MONTH="11" YEAR="2009"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 11:42:53 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="7" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Consumer-written plain language summary added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-18 10:55:31 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Psychiatrische Klinik, Klinikum rechts der Isar, TU München, Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Bundesministerium für Bildung und Forschung, Nr FKZ: 01KG 0606,GZ:GF-GFKG01100506</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-07 09:48:34 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-08-07 09:48:34 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-28 14:59:38 +0000" MODIFIED_BY="[Empty name]">Sertindole versus other atypical antipsychotics for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2009-08-07 09:48:34 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is a mental health problem that can be long term and can severely disable some of the people who have it, especially in terms of quality of life and inclusion into wider society. The main treatment is medication (antipsychotics) and while some people find a drug which decreases their symptoms and does not give them a lot of adverse effects, there are others who are &#8216;treatment resistant&#8217; i.e. none of the medication available works for them. There are some antipsychotics, such as clozapine and sertindole that can have quite dangerous side-effects in some people. However, if they benefit people for whom nothing else works, the extra monitoring of these side-effects that is needed, can perhaps be justified. </P>
<P>This review aims to compare sertindole to the other newer second generation (atypical) antipsychotics in people who have schizophrenia. Two studies were identified which included 508 people. Both compared sertindole to risperidone, were short (12 weeks) and the participants were either at least moderately ill or treatment resistant. There was no overall significant difference between these two medications in terms of improvement in people&#8217;s general well-being or their mental state. Also while people on risperidone showed more movement side-effects, those on sertindole were more likely to put on weight, have changes in their heart rhythm and the men were more likely to suffer from sexual dysfunction. </P>
<P>The data from these trials are limited and a considerable number of the participants left the study early. In addition, sertindole has only been compared to one second generation antipsychotic and the trials are relatively short. A larger and longer trial comparing sertindole to other second generation antipsychotics, with the outcomes including mental state, general functioning, adverse effects and quality of life, would enhance our knowledge in this area considerably.</P>
<P>(Plain language summary prepared for this review by Janey Antoniou of RETHINK, UK <A HREF="http://www.rethink.org">www.rethink.org</A>).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-02-18 14:00:09 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-02-16 10:59:07 +0000" MODIFIED_BY="[Empty name]">
<P>In many countries of the industrialised world second generation (atypical) antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether and, if so, how much the effects of the various second generation antipsychotics differ is a matter of debate.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-10-17 11:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects of sertindole compared with other second generation antipsychotics for people with schizophrenia and schizophrenia-like psychosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-02-18 14:00:09 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group Trials Register (April 2007) and ClinicalTrials.gov (February 2009).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-02-16 10:59:35 +0000" MODIFIED_BY="[Empty name]">
<P>We included all randomised trials comparing oral sertindole with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychosis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-02-18 11:00:15 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted data independently. For dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated weighted mean differences (WMD) again based on a random-effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-02-18 11:00:31 +0000" MODIFIED_BY="[Empty name]">
<P>The review currently includes two short-term low-quality randomised trials (total n=508) both comparing sertindole with risperidone. One third of participants left the studies early (2 RCTs, n=504, RR 1.23 CI 0.94 to 1.60). There was no difference in efficacy (2 RCTs, n=493, WMD PANSS total change from baseline 1.98 CI -8.24 to 12.20). Compared with relatively high doses of risperidone (between 4 and 12 mg/day), sertindole produced significantly less akathisia and parkinsonism (1 RCT, n=321, RR 0.24 CI 0.09 to 0.69, NNT 14, CI 8 to 100). Sertindole produced more cardiac effects (2 RCTs, n=508, RR QTc prolongation 4.86 CI 1.94 to 12.18), weight change (2 RCTs, n=328, WMD 0.99 CI 0.12 to 1.86) and male sexual dysfunction (2 RCTs, n=437, RR 2.90 CI 1.32 to 6.35, NNH 13 CI 8 to 33).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-02-18 11:01:34 +0000" MODIFIED_BY="[Empty name]">
<P>Sertindole may induce fewer movement disorders, but more cardiac effects, weight change and male sexual dysfunction than risperidone. However these data are based on only two studies and are too limited to allow firm conclusions. Nothing can be said about the effects of sertindole compared with second generation antipsychotics other than risperidone. There are several relevant trials underway or completed and about to report.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-02-18 14:39:13 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-02-18 11:15:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CONDITION MODIFIED="2009-02-18 11:14:26 +0000" MODIFIED_BY="[Empty name]">
<P>Conventional antipsychotic drugs such as chlorpromazine and haloperidol have traditionally been used as first line antipsychotics for people with schizophrenia (<LINK REF="REF-Kane-1993" TYPE="REFERENCE">Kane 1993</LINK>). The re-introduction of clozapine in the United States of America and a finding that clozapine was more efficacious and associated with fewer movement disorders than chlorpromazine (<LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>) has boosted the development of so-called "atypical" or new (second) generation antipsychotics.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-02-18 11:09:08 +0000" MODIFIED_BY="[Empty name]">
<P>There is no good definition of what an "atypical" or second generation antipsychotic is, but they were initially said to differ from typical antipsychotics in that they do not cause movement disorders (catalepsy) in rats at clinically effective doses (<LINK REF="REF-Arnt-1998" TYPE="REFERENCE">Arnt 1998</LINK>). The terms "new" or "second generation" antipsychotics are not much better, because clozapine is a very old drug. According to treatment guidelines (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>, <LINK REF="REF-Gaebel-2006" TYPE="REFERENCE">Gaebel 2006</LINK>) second generation antipsychotics include drugs such as amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone and zotepine, although it is unclear whether some old and cheap compounds such as sulpiride or perazine have similar properties (<LINK REF="REF-M_x00f6_ller-2000" TYPE="REFERENCE">Möller 2000</LINK>). The second generation antipsychotics raised major hopes of superior effects in a number of areas such as compliance, cognitive functioning, negative symptoms, movement disorders, quality of life and the treatment of people with treatment-resistant schizophrenia.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-02-18 11:11:29 +0000" MODIFIED_BY="[Empty name]">
<P>Sertindole is a phenylindole derivative (1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl] ethyl-2-imidazolidinone) which is manufactured by Lundbeck Ltd and is sold as Serdolect or Serlect (in several European countries) in 4 mg, 12 mg, 16 mg and 20 mg tablets. It is a long acting 5-HT2 / alpha1 antagonist and a very mild D2 antagonist (<LINK REF="REF-Lewis-2005" TYPE="REFERENCE">Lewis 2005</LINK>). Sertindole may cause QT- prolongation and ventricular tachycardia more than some other atypical antipsychotics. Due to this sertindole was taken from the market in 1998. Since 2002 it has been available again for patient treatment in clinical studies, and since December 2005 it became available again in some European countries: Germany, Estonia, Finland, Hungary, Denmark, Czech Republic, Spain, Slovakia and Greece, (Turkey planned 12/06) under special safety conditions; for example: no first choice treatment, not for emergency treatment, ECG observation (<LINK REF="REF-Lundbeck-2006" TYPE="REFERENCE">Lundbeck 2006</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-02-18 11:15:39 +0000" MODIFIED_BY="[Empty name]">
<P>The debate as to how far the second generation antipsychotics improve these outcomes compared to conventional antipsychotics continues (<LINK REF="REF-Duggan-2005" TYPE="REFERENCE">Duggan 2005</LINK>, <LINK REF="REF-El_x002d_Sayeh-2006" TYPE="REFERENCE">El-Sayeh 2006</LINK>) and the results from recent studies were sobering (<LINK REF="REF-Lieberman-2005" TYPE="REFERENCE">Lieberman 2005</LINK>, <LINK REF="REF-Jones-2006" TYPE="REFERENCE">Jones 2006</LINK>). Nevertheless, in some parts of the world, especially in the highly industrialised countries, second generation antipsychotics have become the mainstay of schizophrenia treatment. The second generation antipsychotics also differ in terms of their costs: while amisulpride is already generic, risperidone will be generic in many countries in 2008. Therefore the question as to whether they differ from each other in their clinical effects becomes increasingly important. In this review we aim to summarise evidence from randomised controlled trials that compared sertindole with other second generation antipsychotics.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To review the effects of sertindole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychosis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-02-18 14:39:13 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-02-18 11:19:03 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-02-18 11:19:03 +0000" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials which were at least single-blind (blind raters). Where a trial was described as 'double-blind', but it was only implied that the study was randomised, we included these trials in a sensitivity analysis. If there was no substantive difference within primary outcomes (see <LINK TAG="CRIT_OUTCOMES" TYPE="SECTION">Types of outcome measures</LINK>) when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only used clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia and other types of schizophrenia-like psychosis (e.g. schizophreniform and schizoaffective disorders), irrespective of the diagnostic criteria used. There is no clear evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Sertindole: any oral form of application, any dose<BR/>2. Other "atypical" antipsychotic drugs: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, zotepine: any oral form of application, any dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-02-05 08:12:53 +0000" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes into the short term (up to 12 weeks), medium term (13-26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-17 21:56:56 +0100" MODIFIED_BY="[Empty name]">
<P>No clinically important response as defined by the individual studies (e.g. global impression less than much improved or less than 50% reduction on a rating scale)</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-02-05 08:12:46 +0000" MODIFIED_BY="[Empty name]">
<P>1. Leaving the studies early (any reason, adverse events, inefficacy of treatment)</P>
<P>2. Global state<BR/>2.1 No clinically important change in global state (as defined by individual studies)<BR/>2.2 Relapse (as defined by the individual studies)</P>
<P>3. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)<BR/>3.1 No clinically important change in general mental state score<BR/>3.2 Average endpoint general mental state score<BR/>3.3 Average change in general mental state score<BR/>3.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia)<BR/>3.5 Average endpoint specific symptom score<BR/>3.6 Average change in specific symptom score</P>
<P>4. General functioning<BR/>4.1 No clinically important change in general functioning<BR/>4.2 Average endpoint general functioning score<BR/>4.3 Average change in general functioning score</P>
<P>5. Quality of life/satisfaction with treatment<BR/>5.1 No clinically important change in general quality of life<BR/>5.2 Average endpoint general quality of life score<BR/>5.3 Average change in general quality of life score</P>
<P>6. Cognitive functioning<BR/>6.1 No clinically important change in overall cognitive functioning<BR/>6.2 Average endpoint of overall cognitive functioning score<BR/>6.3 Average change of overall cognitive functioning score</P>
<P>7. Service use<BR/>7.1 Number of patients hospitalised</P>
<P>8. Adverse effects<BR/>8.1 Number of participants with at least one adverse effect<BR/>8.2 Clinically important specific adverse effects (cardiac effects, death, movement disorders, prolactin increase and associated effects, sedation, seizures, weight gain, effects on white blood cell count)<BR/>8.3 Average endpoint in specific adverse effects<BR/>8.4 Average change in specific adverse effects</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-02-18 14:00:40 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2009-02-18 14:00:40 +0000" MODIFIED_BY="[Empty name]">
<P>1. We searched the Cochrane Schizophrenia Groups Register (April 2007) using the phrase:</P>
<P>[((sertindol* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR risperidon* OR quetiapin* OR ziprasidon* OR zotepin*)) in title, abstract or index terms of REFERENCE) or ((sertindol* AND (amisulprid* OR aripiprazol* OR clozapin* OR olanzapin* OR risperidon* OR quetiapin* OR ziprasidon* OR zotepin*)) in interventions of STUDY)]</P>
<P>This register is compiled by systematic searches of major database, hand searches and conference proceedings (see <A HREF="http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html">Group Module</A>).</P>
<P>2. We searched <A HREF="http://clinicaltrials.gov/">ClinicalTrials.gov</A> (February 2009) using the phrase:</P>
<P>[(schizophrenia OR schizophreniform OR schizoaffective OR schizophrenic OR psychosis OR psychoses OR psychotic OR (tardive AND dyskinesia) OR akathisia) and sertindole]</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-19 00:53:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Reference searching<BR/>We inspected the reference of all identified studies for more trials.</P>
<P>2. Personal contact<BR/>We contacted the first author of each included study for missing information.</P>
<P>3. Drug companies<BR/>We contacted the manufacturers of all atypical antipsychotics included for additional data.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-02-18 14:39:13 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<STUDY_SELECTION MODIFIED="2008-09-18 23:55:19 +0100" MODIFIED_BY="[Empty name]">
<P>We independently inspected all reports. We resolved any disagreement by discussion, and where there was still doubt, we acquired the full article for further inspection. Once the full articles were obtained, we independently decided whether the studies met the review criteria. If disagreement could not be resolved by discussion, we sought further information and these trials were added to the list of those awaiting assessment.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-02-18 11:27:58 +0000" MODIFIED_BY="[Empty name]">
<P>1. Data extraction<BR/>We independently extracted data from selected trials. When disputes arose we attempted to resolve these by discussion. When this was not possible and further information was necessary to resolve the dilemma, we did not enter data and added the trial to the list of those awaiting assessment.</P>
<P>2. Rating scales<BR/>A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, or are even ad hoc. For outcome instruments some minimum standards have to be set. It has been shown that the use of rating scales which have not been described in a peer-reviewed journal are associated with bias (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), therefore we excluded the results of such scales.</P>
<P>3. General<BR/>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for sertindole.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-02-18 14:39:13 +0000" MODIFIED_BY="[Empty name]">
<P>Again working independently, KK and SL assessed risk of bias using the tool described in the Cochrane Collaboration Handbook (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. We would not have included studies where sequence generation was at high risk of bias or where allocation was clearly not concealed.<BR/>
</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-02-18 11:35:45 +0000" MODIFIED_BY="[Empty name]">
<P>1. Data types<BR/>We assessed outcomes using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as "little change", "moderate change" or "much change") or dichotomous (for example, either "no important changes" or "important change" in a person's behaviour) measures. Currently RevMan does not support categorical data so we were unable to analyse this.</P>
<P>2. Dichotomous - yes/no - data<BR/>We carried out an intention to treat analysis. Everyone allocated to the intervention was counted, whether they completed the follow up or not. It was assumed that those who dropped out had no change in their outcome. This rule is conservative concerning response to treatment, because it assumes that those discontinuing the studies would not have responded. It is not conservative concerning adverse effects, but we felt that assuming that all those leaving early would have developed side effects would overestimate risk. Where possible, efforts were made to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into "clinically improved" or "not clinically improved". It was generally assumed that if there had been a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
<P>We calculated the relative risk (RR) and its 95% confidence interval (CI) based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. When the overall results were significant we calculated the number needed to treat (NNT) and the number-needed-to-harm (NNH) as the inverse of the risk difference.</P>
<P>3. Continuous data<BR/>3.1 Normal distribution of the data<BR/>The meta-analytic formulas applied by RevMan Analyses (the statistical programme included in RevMan) require a normal distribution of data. The software is robust towards some skew, but to which degree of skewness meta-analytic calculations can still be reliably carried out is unclear. On the other hand, excluding all studies on the basis of estimates of the normal distribution of the data also leads to a bias, because a considerable amount of data may be lost leading to a selection bias. Therefore, we included all studies in the primary analysis. In a sensitivity analysis we excluded potentially skewed data applying the following rules:</P>
<P>a) When a scale started from the finite number zero the standard deviation, when multiplied by two, was more than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>).<BR/>b) If a scale started from a positive value (such as PANSS which can have values from 30 to 210) the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.<BR/>c) In large studies (as a cut-off we used 200 participants) skewed data pose less of a problem. In these cases we entered the data in a synthesis.<BR/>d) The rules explained in a) and b) do not apply to change data. The reason is that when continuous data are presented on a scale which includes a possibility of negative values, it is difficult to tell whether data are non-normally distributed (skewed) or not. This is also the case for change data (endpoint minus baseline). In the absence of individual patient data it is impossible to know if data are skewed, though this is likely. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in RevMan Analyses in order to summarise available information. In doing this, it was assumed either that data were not skewed or that the analysis could cope with the unknown degree of skew. Without individual patient data it is impossible to test this assumption. Change data were therefore included and a sensitivity analysis was not applied. For continuous outcomes we estimated a weighted mean difference (WMD) between groups. WMDs were again based on the random-effects model, as this takes into account any differences between studies even if there is no statistically significant heterogeneity. We combined both endpoint data and change data in the analysis, because there is no principal statistical reason why endpoint and change data should measure different effects (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). When standard errors instead of standard deviations (SD) were presented, we converted the former to standard deviations. If both were missing we estimated SDs from p-values or used the average SD of the other studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-02-18 11:43:52 +0000" MODIFIED_BY="[Empty name]">
<P>Studies increasingly employ "cluster randomisation" (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intraclass correlation in clustered studies, leading to a "unit of analysis" error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intraclass correlation coefficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a "design effect". This is calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect=1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).<BR/>
<BR/>If cluster studies had been appropriately analysed taking into account intraclass correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-02-18 11:47:06 +0000" MODIFIED_BY="[Empty name]">
<P>Although high rates of premature discontinuation are a major problem in this field, we feel that it is unclear which degree of attrition leads to a high degree of bias. We, therefore, did not exclude trials on the basis of the percentage of participants completing them. However we addressed the drop-out problem in all parts of the review, including the abstract. For this purpose we calculated, presented and commented on frequency statistics (overall rates of leaving the studies early in all studies and comparators pooled and their ranges).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-12-14 08:39:06 +0000" MODIFIED_BY="[Empty name]">
<P>Firstly, we considered all the included studies within any comparison to judge for clinical heterogeneity. Then we visually inspected graphs to investigate the possibility of statistical heterogeneity. This was supplemented using, primarily, the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 50% we interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>)</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-09-19 00:08:46 +0100" MODIFIED_BY="[Empty name]">
<P>We entered data from all identified and selected trials into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias. A formal test for funnel-plot asymmetry was not undertaken.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-02-18 11:48:09 +0000" MODIFIED_BY="[Empty name]">
<P>For both dichotomous and continuous data we used the random-effects model for data synthesis as this takes into account any differences between studies even if there is no statistically significant heterogeneity.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-09-19 00:07:48 +0100" MODIFIED_BY="[Empty name]">
<P>If inconsistency was high and clear reasons explaining the heterogeneity were found, we presented the data separately. If not, we commented on the heterogeneity of the data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-09-19 00:08:18 +0100" MODIFIED_BY="[Empty name]">
<P>In sensitivity analyses we excluded studies with potentially skewed data. A recent report showed that some of the comparisons of atypical antipsychotics may have been biased by using inappropriate comparator doses (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>). We, therefore, also analysed whether the exclusion of studies with inappropriate comparator doses changed the results of the primary outcome and the general mental state.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-02-18 12:13:01 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-02-18 11:58:56 +0000" MODIFIED_BY="[Empty name]">
<P>For substantive description of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2009-02-05 16:52:18 +0000" MODIFIED_BY="[Empty name]">
<P>The search strategy yielded 3620 reports of which five studies were closely inspected.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-02-18 11:58:56 +0000" MODIFIED_BY="[Empty name]">
<P>Two randomised, double-blind studies (508 participants) met the inclusion criteria. One of the studies (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>) has to date only been published as a poster presenting limited information.</P>
<P>1. Length of trials<BR/>Both included studies were short-term studies with a duration of twelve weeks. We identified no medium-term or long-term studies.</P>
<P>2. Participants<BR/>All participants were diagnosed according to the Diagnostic and Statistical Manual Version IV (DSM-IV). <LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK> included people with various subtypes of schizophrenia who had to be at least moderately ill. <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK> included only people who were considered to be treatment resistant. There was a clear preponderance of men (71%) and the participants were relatively chronic with mean ages in the end thirties.</P>
<P>3. Setting<BR/>
<LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK> was conducted in inpatients and outpatients. <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK> did not report on setting.</P>
<P>4. Study size<BR/>The studies included 150 (<LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK>) and 350 people (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>).</P>
<P>5. Interventions<BR/>In both studies sertindole was given in flexible doses. The dose range was between 12 and 24 mg/day with mean doses of 16.2 mg/day in <LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK> and 18.1 mg/day in <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>.</P>
<P>Risperidone was the comparator drug in both studies. In <LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK> the dose range was 4 to 10 mg/day (mean 6.6 mg/day) and in <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK> it was 6 to 12 mg/day (mean 9.0 mg/day).</P>
<P>6. Outcomes<BR/>6.1 Leaving the study early<BR/>Both studies reported the number of participants leaving the studies early due to any reason, adverse events and lack of efficacy.</P>
<P>6.2 No clinically significant response to treatment<BR/>We prespecified at least 50% PANSS/BPRS reduction from baseline as a clinically meaningful cut-off score to define response which was indeed presented in <LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK>. <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK> did not report on the outcome 'no clinically significant response'.</P>
<P>6.3 Adverse effects<BR/>Adverse effects were mainly recorded in open interviews. In addition to those listed below continuous data were provided for weight gain, QTc interval and glucose levels.</P>
<P>6.4 Outcome scales<BR/>Details of scales that provided usable data are shown below.</P>
<P>6.4.1 Global state scales<BR/>6.4.1.1 Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system used low scores showing decreased severity and/or overall improvement.</P>
<P>6.4.2 Mental state scales<BR/>6.4.2.1 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. It can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates less severity.</P>
<P>6.4.3 Global Assessment of Functioning- GAF (<LINK REF="REF-APA-2004" TYPE="REFERENCE">APA 2004</LINK>)<BR/>A rating scale for a patients overall capacity of psychosocial functioning scoring from 1-100. Higher scores indicate a higher level of functioning.</P>
<P>6.4.4 Adverse effects scales<BR/>6.4.4.1 Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder and short-term movement disorders such as tremor.</P>
<P>6.4.4.2 Barnes Akathisia Scale - BAS (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>The scale comprises items rating the observable, restless movements that characterise akathisia, a subjective awareness of restlessness, and any distress associated with the condition. These items are rated from 0 - normal to 3 - severe. In addition, there is an item for rating global severity (from 0 - absent to 5 - severe). A low score indicates low levels of akathisia.</P>
<P>6.4.4.3 Simpson Angus Scale - SAS (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This ten-item scale, with a scoring system of 0 to 4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.</P>
<P>6.5 Missing outcomes<BR/>Our primary outcome was 'No clinically important response as defined by the individual studies' (e.g. global impression less than much improved or less than 50% reduction on a rating scale). We identified no useable data on relapse, quality of life/satisfaction with treatment, cognitive functioning, or service use.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-02-17 14:05:14 +0000" MODIFIED_BY="[Empty name]">
<P>Four studies had to be excluded (<LINK REF="STD-Nielsen-2006" TYPE="STUDY">Nielsen 2006</LINK>, <LINK REF="STD-Perro-1999" TYPE="STUDY">Perro 1999</LINK>; <LINK REF="STD-Potkin-1996" TYPE="STUDY">Potkin 1996</LINK>, <LINK REF="STD-Zurich-2008" TYPE="STUDY">Zurich 2008</LINK>). All but <LINK REF="STD-Zurich-2008" TYPE="STUDY">Zurich 2008</LINK> were randomised, but <LINK REF="STD-Perro-1999" TYPE="STUDY">Perro 1999</LINK> was open label. The other two compared sertindole with treatments not relevant to this review. </P>
<SUBSECTION>
<HEADING LEVEL="4">Studies awaiting assessment</HEADING>
<P>No studies are awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>We identified eight studies that seem to be ongoing or recently completed (<LINK REF="STD-Cheung-2005" TYPE="STUDY">Cheung 2005</LINK>, <LINK REF="STD-Lundbeck-2006a" TYPE="STUDY">Lundbeck 2006a</LINK>, <LINK REF="STD-Lundbeck-2006b" TYPE="STUDY">Lundbeck 2006b</LINK>, <LINK REF="STD-Lundbeck-2007a" TYPE="STUDY">Lundbeck 2007a</LINK>, <LINK REF="STD-Lundbeck-2008" TYPE="STUDY">Lundbeck 2008</LINK>, <LINK REF="STD-Sireling-2003" TYPE="STUDY">Sireling 2003</LINK>, <LINK REF="STD-Spaniel-2008" TYPE="STUDY">Spaniel 2008</LINK>, <LINK REF="STD-Weiser-2007" TYPE="STUDY">Weiser 2007</LINK>). These should report on a variety of clinical outcomes on a total of over 800 people with schizophrenia from right across the world in the next year or so. It is clear that this is an area of considerable research interest and activity. </P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-02-18 12:00:30 +0000" MODIFIED_BY="[Empty name]">
<P>For graphical representations of our judgements please refer to risk of bias <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. Full details of judgements are seen in the Risk of Bias tables.</P>
<ALLOCATION MODIFIED="2009-01-28 15:14:54 +0000" MODIFIED_BY="[Empty name]">
<P>Both included studies were described as randomised, but further details on the randomisation method were not provided. Therefore whether adequate randomisation and allocation methods were used is unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-02-16 10:55:33 +0000" MODIFIED_BY="[Empty name]">
<P>Both included studies were double-blind, <LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK> used identical capsules for blinding, while <LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK> did not provide any details on the blinding procedure. Whether blinding was effective is unclear. Neither study examined this. The adverse effect profiles of both compounds are quite different which may have made blinding difficult. Therefore, the risk of bias for objective outcomes (e.g. death or laboratory values) may have been low, but there was a risk of bias for subjective outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-02-03 16:27:58 +0000" MODIFIED_BY="[Empty name]">
<P>Both studies had a considerably high overall attrition rate (33%) which might limit the validity of findings. Both studies applied the last-observation-carried-forward method to account for participants leaving the study early which is an imperfect method. It assumes that a participant who left the study prematurely would not have had a change of his condition if he had stayed in the study. This assumption can obviously be wrong.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-02-16 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Only those adverse events that occurred in at least 5% (<LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK>) or 10% (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>) of the participants were reported. This procedure is problematic, because rare, but potentially serious adverse effects may not have been reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-02-18 12:00:30 +0000" MODIFIED_BY="[Empty name]">
<P>Both studies were sponsored by the pharmaceutical company producing sertindole. In one study (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>) the lower dose range for risperidone was rather high (6mg). Such a high dose may have led to a relatively high amount of extrapyramidal side-effects in the risperidone group. Both studies were industry sponsored by the manufacturers of sertindole. It has been shown that pharmaceutical companies tend to emphasize the advantages of their drugs and to highlight the problems of the comparator compound (<LINK REF="REF-Heres-2006" TYPE="REFERENCE">Heres 2006</LINK>).<BR/>
</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-02-18 12:13:01 +0000" MODIFIED_BY="[Empty name]">
<P>1. Two studies comparing sertindole with risperidone met the inclusion criteria, data on other comparisons are not available.</P>
<P>2. Comparison 1: SERTINDOLE versus RISPERIDONE</P>
<P>2.1 Leaving the study early<BR/>Data on leaving the study early did not show a significant difference in numbers leaving the study early because of any reason (2 RCTs, n=504, RR 1.23 CI 0.94 to 1.60), adverse effects (2 RCTs, n=504, RR 1.38 CI 0.74 to 2.57) and inefficacy (2 RCTs, n=504, RR 1.32 CI 0.80 to 2.18).</P>
<P>2.2 Global state<BR/>2.2.1 No clinically significant response - as defined by the original studies<BR/>There was no significant difference between groups (1 RCT, n=187, RR 0.88 CI 0.71 to 1.08).</P>
<P>2.2.2 Global state: no clinically important change<BR/>There was no significant difference (1 RCT, n=187, RR 0.81 CI 0.59 to 1.10).</P>
<P>2.3 General mental state<BR/>2.3.1 No clinically important change (less than 50% PANSS total score reduction)<BR/>There was no significant difference (1 RCT, n=187, RR 0.88 CI 0.71 to 1.08).</P>
<P>2.3.2 PANSS total score (high=poor)<BR/>Overall there was no significant difference ( 2 RCTs, n=493, WMD 1.98 CI -8.24 to 12.20) but results were heterogenous. In one study in treatment-resistant participants risperidone was significantly superior (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>: n=321, MD 6.94 CI 1.74 to 12.14), while in the other which did not use such a criterion there was a trend in favour of sertindole (<LINK REF="STD-Azorin-2006" TYPE="STUDY">Azorin 2006</LINK>: n=172, MD -3.50 CI -10.42 to 3.42).</P>
<P>2.3.3 Positive Symptoms: PANSS positive subscore (high=poor)<BR/>There was no significant difference (1 RCT, n=187, MD -0.80 CI -2.95 to 1.35).</P>
<P>2.3.4 Negative Symptoms: PANSS negative subscore (high=poor)<BR/>There was no significant difference (1 RCT, n=187, MD -1.30 CI -3.13 to 0.53).</P>
<P>2.4 General functioning: GAF total score<BR/>There was no significant difference (1 RCT, n=114, MD -2.90 CI -8.41 to 2.61).</P>
<P>2.5 Adverse effects<BR/>2.5.1 At least one adverse effect<BR/>There was no significant difference (2 RCTs, n=504, RR 1.03 CI 0.95 to 1.11).</P>
<P>2.5.2 Death<BR/>There was no significant difference in terms of suicide (1 RCT, n=187, RR 0.30 CI 0.01 to 7.34).</P>
<P>2.5.3 Cardiac effects - number of participants with QTc prolongation<BR/>Significantly more participants in the sertindole group showed QTc prolongation (2 RCTs, n=508, RR 4.86 CI 1.94 to 12.18, NNH not estimable). The mean increase of the QTc interval was larger in the sertindole group (2 RCTs, n=495, WMD 18.60 CI 14.83 to 22.37).</P>
<P>2.5.4 Central nervous system<BR/>2.5.4.1 Sedation<BR/>There was no significant difference (2 RCTs, n=508, RR 0.87 CI 0.52 to 1.44).</P>
<P>2.5.4.2 Extrapyramidal adverse effects<BR/>Data on extrapyramidal side effects indicated a significant superiority of sertindole in terms of akathisia (1 RCT, n=321, RR 0.45 CI 0.20 to 0.98, NNT not estimable) and parkinsonism (1 RCT, n=321, RR 0.24 CI 0.09 to 0.69, NNT 14 CI 8 to 100), while there were no significant differences in terms of any extrapyramidal symptoms (1 RCT, n=187, RR 0.65 CI 0.38 to 1.11) or tremor (1 RCT, n=187, RR 1.51 CI 0.37 to 6.15). There was no significant difference in the mean values of rating scales in dyskinesia (AIMS: 2 RCTs, n=477, WMD -0.31 CI -0.86 to 0.25) and general EPS (SAS: 2 RCTs, n=500, WMD -0.46 CI -1.24 to 0.32), but there was a significant benefit for sertindole in akathisia (BAS: 2 RCTs, n=500, WMD -0.22 CI -0.41 to -0.03).</P>
<P>2.5.5 Metabolic<BR/>2.5.5.1 Cholesterol - change from baseline in mg/dl<BR/>There was no significant difference (1 RCT, n=176, MD -4.90 CI-13.53 to 3.73).</P>
<P>2.5.5.2 Glucose - mean change from baseline in mg/dl<BR/>There was no significant difference (1 RCT, n=176, WMD -2.00 CI -9.85 to 5.85).</P>
<P>2.5.5.3 Weight<BR/>There was no significant difference for weight gain (1 RCT, n=187, RR 1.30 CI 0.70 to 2.41) but there was a significant difference for the change in weight from baseline in kg, favouring risperidone (2 RCTs, n=328, WMD 0.99 CI 0.12 to 1.86).</P>
<P>2.6 Sexual dysfunction<BR/>Sertindole produced more sexual side effects in men (2 RCTs, n=437, RR 2.90 CI 1.32 to 6.35, NNH 13 CI 8 to 33).</P>
<P>3. Publication bias<BR/>Due to the small number of included studies a funnel plot analysis was not performed.</P>
<P>4. Investigation for heterogeneity and sensitivity analysis<BR/>The reasons for the preplanned sensitivity analyses did not apply and they were therefore not performed.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-02-18 12:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>The current review only includes two short-term, low-quality randomised trials comparing sertindole with risperidone. A considerable number of participants leaving the studies early of 33.7% limits the interpretation of the findings. Currently (early 2009) perhaps one of the most important findings is the considerable research activity in this area. We expect several large relevant trials to begin to be presented and published this year.</P>
<SUMMARY_OF_RESULTS MODIFIED="2009-02-18 12:16:43 +0000" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>To date only two studies comparing sertindole with risperidone have been published. There are no available data on the effects of sertindole compared to amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, ziprasidone or zotepine. The overall number of participants leaving the studies early of 33.7% was considerable and calls the validity of the findings into question, because many data have to been guessed by statistical modelling. Both studies were short term which is far from ideal for judging the relative tolerability and efficacy of antipsychotic drugs in a chronic disease like schizophrenia. Both included trials were sponsored by the manufacturer of sertindole and the study showing sertindole to be less efficacious has, to date, only been presented as a poster and reports few data (<LINK REF="STD-Kane-2005" TYPE="STUDY">Kane 2005</LINK>).</P>
<P>2. Comparison 1: SERTINDOLE versus RISPERIDONE<BR/>2.1 Leaving the studies early<BR/>Although the number of participants leaving the studies early due to any reason was considerable (33.7%), there was no significant difference between sertindole and risperidone suggesting similar [rather poor] overall acceptability of treatment. Specific reasons for leaving the studies early (adverse events, inefficacy of treatment) also did not show a difference between both compounds.</P>
<P>2.2 Efficacy: global outcomes, mental state outcomes<BR/>There was no clear difference in efficacy based on CGI, PANSS, PANSS positive and negative subscores. Nevertheless, the results on the general mental state as measured by the PANSS total score were heterogeneous. One study suggested that, for people with treatment-resistant schizophrenia, risperidone may be somewhat more effective, while in the other study without this criterion no difference was found. Any interpretation is certainly limited by the small number of included trials and participants. Replication is needed.</P>
<P>2.3 Functioning<BR/>Only one short-term study provided data on general functioning and showed no difference between groups. We believe that long-term studies are needed to examine this outcome.</P>
<P>2.4 Adverse effects<BR/>There were data on extrapyramidal symptoms, cardiac effects, cholesterol, glucose, sedation, sexual dysfunction, suicide and weight gain.</P>
<P>These limited data suggest that akathisia and parkinsonism may occur less frequently with sertindole than with risperidone. However, relatively high risperidone dose ranges of 4 to 10 mg/day and 4 to 12 mg/day in the included studies must be taken into account. On the other hand cardiac effects (QTc prolongation), male sexual dysfunction and weight change indicated a benefit for risperidone. These differences in tolerability may be considered in drug choice. Due to the known effects of sertindole on the QTc interval the drug can not be recommended for people with schizophrenia and at risk of cardiac problems.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-02-18 12:17:36 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised evidence is available for only one out of eight possible comparisons of sertindole with other second generation antipsychotic drugs. For most comparisons not a single study was identified and the evidence is therefore very incomplete. One of the available studies has, as far as we know, only been presented as a poster. In terms of applicability of the evidence we highlight that both studies were short-term and that long-term effectiveness studies are not available, clearly limiting external validity.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-02-18 12:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>Both studies were randomised and double-blind but some details were presented only for one study (use of identical capsules for blinding). Neither study explored whether blinding was successful. There was also a high risk of bias in terms of incomplete outcome reporting, selective reporting and other biases in both studies. Therefore the overall quality of the evidence is rather low.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-02-16 10:57:56 +0000" MODIFIED_BY="[Empty name]">
<P>The search for studies is largely based on the Cochrane Schizophrenia Group&#8217;s register of trials. This is largely made up of searches of already published literature. It is possible that there are unpublished studies we are not aware of. We have not been granted lists of such studies by the relevant company.</P>
<P>This review only includes double-blinded studies. This could influence the review. As this is not a technique used in clinical practice, the interventions used in the studies in this review are also not used in clinical practice. It is not blind administration that happens day to day - it is the open giving of treatments. As open giving has not been evaluated in this review the findings may be biased towards the experimental situation and away from the real world. This could have advantages of the potential for more objective evaluation of outcome. Objective evaluation of outcome is, of course of great value but only when its difference to the less objective assessment of the real world is understood. By understanding the difference between the two, on the assumption that one set of ratings is truly objective and the other approximates the real world, we can get a feel for what proportion of the effects are generated by the &#8216;openness&#8217;. Having said this, we have noted that it may have been difficult to blind the trials and several of the so called blind outcomes could well have been open. This issue was untested in these &#8220;double-blind&#8221; studies. Conversly we are unsure of the proportion of data in the open study we have excluded that we think may not have been effected by blindness &#8211; for example outcomes such as death or leaving early. In this version of the review, however, we have omitted the open label studies. It may be, in future versions of this review we include these for at least sensitivity analyses. </P>
<P>We have chosen to use the random-effects model for our analyses. We do so because this model does not assume that the populations from which the different trials are derived are the same. This is, of course, true. However, use of this technique does emphasise the results from smaller trials and it is these studies that are likely to be most prone to bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-02-16 09:53:29 +0000" MODIFIED_BY="[Empty name]">
<P>A previous systematic review compared sertindole with any other treatment (<LINK REF="REF-Lewis-2005" TYPE="REFERENCE">Lewis 2005</LINK>). It could not draw a conclusion on the effects of sertindole compared to other second generation antipsychotic drugs, because, at that time, no relevant studies were available.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-02-18 12:33:38 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-02-18 12:33:38 +0000" MODIFIED_BY="[Empty name]">
<P>1. For people with schizophrenia<BR/>For people with schizophrenia it is important to know that overall no clear difference in efficacy between sertindole and risperidone has been shown. Sertindole may induce certain movement disorders (inner restlessness and symptoms that mimic Parkinson's disease) less frequently than risperidone, but on the other hand sertindole may lead to more cardiac problems (QTc prolongation - a potentially life threatening heart rate variability), weight change and male sexual dysfunction.</P>
<P>2. For clinicians<BR/>Except for risperidone, no randomised evidence compares sertindole with other second generation antipsychotic drugs. Even compared to risperidone only two, insufficiently reported randomised trials are available making clear recommendations impossible and making more studies to clarify sertindole's role compared to other second generation antipsychotic drugs a matter of urgency. Nevertheless, sertindole may be as effective as risperidone. It may induce fewer movement disorders than risperidone - at least when the latter is given in relatively high doses (between 4 and 12 mg/day). However, sertindole may be associated with more QTc prolongation, weight change, and male sexual dysfunction.<BR/>
</P>
<P>3. For managers/policy makers<BR/>Long-term studies reporting on outcomes such as cost effectiveness, service utilisation or functioning in society that are necessary for policy makers are simply not available. Nevertheless, it may be important for them to know that risperidone has lost its patent and is therefore available as a generic in many countries which may be a cheaper alternative than sertindole.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-02-17 15:03:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. General<BR/>Outcome reporting remains insufficient in antipsychotic drug trials. Strict adherence to the <A HREF="http://www.consort-statement.org">CONSORT</A> statement would make such studies much more informative (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>). We look forward to this in the new generation of studies that should be beginning to be reported soon. </P>
<P>2. Specific<BR/>Future versions of this review may include a Summary of Findings table. There is also further work to be done investigating the effects of including studies that are open. It may be that we have lost some - although not much - data by exclusion of <LINK REF="STD-Perro-1999" TYPE="STUDY">Perro 1999</LINK>. In addition, it is important to follow up all ongoing work to see if these studies provide additional data. Should these sources of data not be likely to provide more definitive findings, as currently only two trials compare sertindole with risperidone are available, there is an urgent need for studies comparing sertindole with other second generation antipsychotics. We have outlined a suggested design in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-02-18 12:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank all members of the Cochrane Schizophrenia Group editorial team for their editorial assistance.<BR/>We would also like to thank the pharmaceutical company Lundbeck for providing additional information on the studies.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-02-18 12:52:25 +0000" MODIFIED_BY="[Empty name]">
<P>Katja Komossa - none known.<BR/>Stefan Leucht - received speaker/consultancy honoraria from Sanofi-Aventis, BMS, Eli Lilly, Janssen, Lundbeck and Pfizer. He received research support from Sanofi-Aventis and Eli Lilly.<BR/>Cristine Rummel - received lecture honoraria and travel grants to attend scientific meetings from AstraZeneca, Janssen-Cilag, Eli Lilly and Pfizer. <BR/>Werner Kissling: received speaker or consultancy honoraria from SanofiAventis, BMS, Lilly, Janssen, Lundbeck, Bayer and Pfizer.<BR/>Heike Hunger - none known.<BR/>Franziska Schmidt - none known.<BR/>Sandra Schwarz - none known.<BR/>Ruth Lewis - none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-02-18 14:41:14 +0000" MODIFIED_BY="[Empty name]">
<P>Katja Komossa - protocol development, searching, study selection, data extraction, report writing.<BR/>Christine Rummel - protocol development, searching, study selection.<BR/>Stefan Leucht - protocol development, searching, study selection, data extraction, report writing.<BR/>Werner Kissling - protocol development.<BR/>Heike Hunger - helped with data extraction and writing.<BR/>Franziska Schmid - helped with data extraction and writing.<BR/>Sandra Schwarz - helped with data extraction and writing.<BR/>Ruth Lewis - protocol development.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-02-18 12:52:32 +0000" MODIFIED_BY="[Empty name]">
<P>The review was slightly adapted to new functions available in Review Manager 5, namely the risk of bias tables.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-02-17 15:09:00 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-02-17 15:09:00 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-02-05 17:39:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Azorin-2006" MODIFIED="2008-12-22 13:28:49 +0000" MODIFIED_BY="[Empty name]" NAME="Azorin 2006" YEAR="2005">
<REFERENCE MODIFIED="2008-12-22 13:28:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Azorin JM, Strub N, Loft H</AU>
<TI>A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>1</NO>
<PG>49-56</PG>
<CY>England</CY>
<IDENTIFIERS MODIFIED="2008-12-17 11:51:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kane-2005" MODIFIED="2008-12-17 11:51:27 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-12-17 11:51:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Potkin S, Buckley P, Daniel DG</AU>
<TI>Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>490</PG>
<IDENTIFIERS MODIFIED="2008-12-17 11:51:27 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-02-17 15:09:00 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Nielsen-2006" MODIFIED="2009-02-17 13:05:58 +0000" MODIFIED_BY="[Empty name]" NAME="Nielsen 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-02-17 13:05:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nielsen J, Munk-Jorgensen P</AU>
<TI>Augmenting clozapine with sertindole - a double blinded randomized placebo study</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>2006</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00345982"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perro-1999" MODIFIED="2009-02-16 20:46:54 +0000" MODIFIED_BY="[Empty name]" NAME="Perro 1999" YEAR="">
<REFERENCE MODIFIED="2009-02-16 20:46:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Perro C, Naber D, Lambert M, Moritz S, Krause M</AU>
<TI>A prospective clinical comparative-study of four atypical antipsychotic agents in the treatment of schizophrenia</TI>
<SO>Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany</SO>
<YR>1999</YR>
<PG>13</PG>
<CY>Hamburg</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Potkin-1996" MODIFIED="2009-02-16 20:19:24 +0000" MODIFIED_BY="[Empty name]" NAME="Potkin 1996" YEAR="">
<REFERENCE MODIFIED="2009-02-16 20:19:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Potkin SG, Zhobrowsky JN, Wu JC, Mack JC, Sebree TB, Wallin BC</AU>
<TI>Brain imaging to determine the effects of sertindole in schizophrenic patients.</TI>
<SO>Proceeding of the 149th Annual Meeting of the American Psychiatric Association;1996 May 4-9; New York, USA</SO>
<YR>1996</YR>
<PB>American Psychiatric Association</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2008-12-17 11:51:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zurich-2008" MODIFIED="2009-02-17 15:09:00 +0000" MODIFIED_BY="[Empty name]" NAME="Zurich 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-02-17 15:09:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>University of Zurich</AU>
<TI>The effect of sertindole on sensory gating and cognition in schizophrenic patients</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>2008</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00629252"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-02-17 15:08:33 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Cheung-2005" MODIFIED="2009-02-17 15:07:02 +0000" MODIFIED_BY="[Empty name]" NAME="Cheung 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-17 15:06:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cheung HK</AU>
<TI>Sertindole versus risperidone safety outcome study: A randomised, partially-blinded, parallel-group, active-controlled, post-marketing study</TI>
<SO>http://www.ekg.org.hk/HAREC-CTR/index.jsp</SO>
<YR>2005</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="HAREC-CTR (9) in L/M (266) in TMH/CON/ADM/39"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-17 12:18:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cheung HK</AU>
<TI>Sertindole versus risperidone safety outcome study: a randomised, partially-blinded, parallel-group, active-controlled, post-marketing study</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2009-02-17 12:18:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER MODIFIED="2009-02-17 12:18:41 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT00563550"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-17 15:07:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lundbeck H</AU>
<TI>A prospective randomised partially-blinded parallel-group active-controlled study of sertindole in schizophrenia</TI>
<SO>http://www.lundbecktrials.com/</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2009-02-17 12:20:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER MODIFIED="2009-02-17 12:20:59 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Lundbeck ID 99824"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundbeck-2006a" MODIFIED="2009-02-17 15:07:19 +0000" MODIFIED_BY="[Empty name]" NAME="Lundbeck 2006a" YEAR="2006">
<REFERENCE MODIFIED="2009-02-17 15:07:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lundbeck H</AU>
<TI>A prospective randomised double-blind parallel-group active-referenced trial of sertindole in schizophrenia</TI>
<SO>http://www.lundbecktrials.com/</SO>
<YR>2006</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="Lundbeck ID 11286"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundbeck-2006b" MODIFIED="2009-02-17 15:07:32 +0000" MODIFIED_BY="[Empty name]" NAME="Lundbeck 2006b" YEAR="2006">
<REFERENCE MODIFIED="2009-02-17 15:07:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lundbeck H</AU>
<TI>Exploratory cognition study of sertindole in patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>2006</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00759421"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundbeck-2007a" MODIFIED="2009-02-17 15:07:42 +0000" MODIFIED_BY="[Empty name]" NAME="Lundbeck 2007a" YEAR="2007">
<REFERENCE MODIFIED="2009-02-17 15:07:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lundbeck H</AU>
<TI>Study on metabolic parameters of sertindole in patients' with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00759460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundbeck-2008" MODIFIED="2009-02-17 12:32:39 +0000" MODIFIED_BY="[Empty name]" NAME="Lundbeck 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-02-17 12:32:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lundbeck H</AU>
<TI>Efficacy study exploring the effects on cognition of sertindole versus comparator in patients with schizophrenia</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>2008</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00654706"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sireling-2003" MODIFIED="2009-02-16 20:50:15 +0000" MODIFIED_BY="[Empty name]" NAME="Sireling 2003" YEAR="">
<REFERENCE MODIFIED="2009-02-16 20:50:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sireling 2003</AU>
<TI>Study a) Sertindole versus risperidone safety outcome study: a randomised, partially blinded, parallel-group, active-controlled, post marketing study. Study b) Sertindole post-marketing surveillance study</TI>
<SO>National Research Register</SO>
<YR>2003</YR>
<VL>2</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spaniel-2008" MODIFIED="2009-02-17 15:08:04 +0000" MODIFIED_BY="[Empty name]" NAME="Spaniel 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-02-17 15:08:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Prague Psychiatric Center, Eli Lilly</AU>
<TI>Study with information technology (IT) - aided preventive program in schizophrenia</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>2008</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00712660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-02-17 13:00:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spaniel F, Vohlídka P, Hrdlicka J, Kozený J, Novák T, Motlová L, Cermák J, Bednarík J, Novák D, Höschl C</AU>
<TI>ITAREPS: information technology aided relapse prevention programme in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2008</YR>
<VL>98</VL>
<NO>1-3</NO>
<PG>312-7</PG>
<IDENTIFIERS MODIFIED="2009-02-17 13:00:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-17 13:00:07 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17920245"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiser-2007" MODIFIED="2009-02-17 15:08:33 +0000" MODIFIED_BY="[Empty name]" NAME="Weiser 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-02-17 15:08:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Weiser M, Abramovitz Y, Teitelbaum A</AU>
<TI>Comparison of cognitive functions of schizophrenic patients treated with sertindole versus risperidone</TI>
<SO>http://www.clinicaltrials.gov/</SO>
<YR>2007</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE=""/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00480844"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-02-17 13:23:06 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2009-02-16 20:33:34 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" MODIFIED="2009-02-02 19:20:11 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS MODIFIED="2009-02-02 19:20:11 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-APA-2004" MODIFIED="2009-02-16 20:21:15 +0000" MODIFIED_BY="[Empty name]" NAME="APA 2004" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Practice guidelines for the treatment of patients with schizophrenia</SO>
<YR>2004</YR>
<PG>1-114</PG>
<EN>2nd</EN>
<PB>American Journal of Psychiatry</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnt-1998" NAME="Arnt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Arnt J, Skarsfeldt T</AU>
<TI>Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence</TI>
<SO>Neuropsychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<PG>63-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2009-02-16 20:21:37 +0000" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2009-02-16 20:24:57 +0000" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<PB>Cochrane Collabor</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2005" MODIFIED="2008-11-10 09:45:06 +0000" MODIFIED_BY="[Empty name]" NAME="Duggan 2005" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-10 09:45:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-10 09:45:06 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Sayeh-2006" MODIFIED="2009-02-16 20:27:19 +0000" MODIFIED_BY="[Empty name]" NAME="El-Sayeh 2006" TYPE="COCHRANE_REVIEW">
<AU>El-Sayeh HG, Morganti C</AU>
<TI>Aripiprazole for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<PB>Wiley and Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2009-02-16 20:27:19 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-16 20:27:19 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004578.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gaebel-2006" NAME="Gaebel 2006" TYPE="OTHER">
<AU>Gaebel W, Falkai P, Weinmann S, Wobrock T</AU>
<TI>Treatment guidelines for schizophrenia</TI>
<TO>Behandlungsleitlinie Schizophrenie</TO>
<SO>Steinkopf</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2009-02-16 20:28:17 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="OTHER">
<AU>Guy U</AU>
<TI>ECDEU assessment manual for psychopharmacology</TI>
<SO>National Institute of Mental Health</SO>
<YR>1976</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heres-2006" NAME="Heres 2006" TYPE="JOURNAL_ARTICLE">
<AU>Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S</AU>
<TI>Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<PG>185-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-02-16 20:29:47 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]</TI>
<SO>The Cochrane Colllaboration</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-2006" NAME="Jones 2006" TYPE="JOURNAL_ARTICLE">
<AU>Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW</AU>
<TI>Randomized controlled trial of the effect on quality of life</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2006</YR>
<VL>63</VL>
<PG>1079-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" MODIFIED="2009-02-02 19:21:10 +0000" MODIFIED_BY="[Empty name]" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group</AU>
<TI>Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS MODIFIED="2009-02-02 19:21:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1993" NAME="Kane 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment programme and long term outcome in chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>46</VL>
<PG>585-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and negative syndrome scale (PANSS) manual</SO>
<YR>1986</YR>
<PB>Multi-Health Systems</PB>
<CY>North Tonawanda (NY)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lewis-2005" MODIFIED="2009-02-16 20:32:35 +0000" MODIFIED_BY="[Empty name]" NAME="Lewis 2005" TYPE="COCHRANE_REVIEW">
<AU>Lewis R, Bagnall A-M, Leitner M</AU>
<TI>Sertindole for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>Issue 3</NO>
<IDENTIFIERS MODIFIED="2009-02-16 20:32:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-16 20:32:35 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001715.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lieberman-2005" MODIFIED="2009-02-02 19:21:42 +0000" MODIFIED_BY="[Empty name]" NAME="Lieberman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM</AU>
<TI>Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>1209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundbeck-2006" MODIFIED="2009-02-16 20:32:55 +0000" MODIFIED_BY="[Empty name]" NAME="Lundbeck 2006" TYPE="OTHER">
<AU>Lundbeck</AU>
<TI>Sertindole product information</TI>
<SO>Lundbeck Ltd</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2009-02-16 20:33:12 +0000" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D</AU>
<TI>The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-M_x00f6_ller-2000" NAME="Möller 2000" TYPE="JOURNAL_ARTICLE">
<AU>Möller HJ</AU>
<TI>New assessment of atypical antipsychotics</TI>
<TO>Aktuelle Bewertung neuer/atypischer Neuroleptika</TO>
<SO>Nervenarzt</SO>
<YR>2000</YR>
<VL>71</VL>
<PG>329-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2009-02-16 20:33:34 +0000" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2008-10-18 12:48:05 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson EN, Angus JWF</AU>
<TI>A rating scale for extrapyramidal side-effects</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2009-02-02 19:22:09 +0000" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>iii-92</PG>
<IDENTIFIERS MODIFIED="2009-02-02 19:22:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-02-16 20:39:42 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Leucht-2008" MODIFIED="2009-02-16 20:39:42 +0000" MODIFIED_BY="[Empty name]" NAME="Leucht 2008" TYPE="OTHER">
<AU>Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM</AU>
<TI>A meta-analysis of head-to-head comparisons of second-generation antipsychotics of schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2008 epub</YR>
<VL>November 17</VL>
<IDENTIFIERS MODIFIED="2009-02-16 20:36:08 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-16 20:36:08 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1176/appi.ajp.2008.08030368"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2009-02-17 13:23:06 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-02-18 13:20:16 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-02-18 13:15:45 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-02-18 12:53:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Azorin-2006">
<CHAR_METHODS MODIFIED="2009-02-05 08:29:32 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blinding: double, identical capsules.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Setting: inpatient and outpatient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-18 12:52:54 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N=187.<BR/>Gender: 113 M, 73 F (intent-to-treat group).<BR/>Age: 18-65 years (mean ~ 36 years).<BR/>History: duration ill unclear, age at onset unclear, at least moderately ill on CGI-S.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-05 08:43:16 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: flexible dose (permitted range 12-24 mg/day, mean 16.2). N=98.</P>
<P>2. Risperidone: flexible dose (permitted range 4-10 mg/day, mean 6.6). N=89.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-18 12:53:11 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving study early: any reason, adverse effects, inefficacy.<BR/>Global state: CGI.<BR/>Mental state: PANSS (total, positive, negative sub-score).<BR/>Functioning: GAF.<BR/>Attitude: Drug attitude inventory.<BR/>Adverse effect/event: at least one adverse effect, QTc prolongation, death, extrapyramidal side effects (tremor, AIMS, BAS, SAS), prolactin associated effects (amenorrhoea, sexual dysfunction), sedation, weight change.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-02-05 08:49:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kane-2005">
<CHAR_METHODS MODIFIED="2009-02-05 08:37:36 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blinding: double, no further details.<BR/>Duration: 12 weeks.<BR/>Design: parallel.<BR/>Location: multicentre.<BR/>Setting: not specified.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-05 08:40:41 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (DMS-IV).<BR/>N=321.<BR/>Gender: 250 M, 71 F.<BR/>Age: 18-55 years (mean ~39).<BR/>History: duration ill not specified, mean age at onset ~ 22 years, treatment resistance, PANSS total score &#8807; 60.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-05 08:42:58 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: flexible dose (permitted range 12-24 mg/day, mean 18.1). N=216.</P>
<P>2. Risperidone: flexible dose (permitted range 6-12 mg/day, mean 9). N=105.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-05 08:49:48 +0000" MODIFIED_BY="[Empty name]">
<P>Leaving study early: any reason, adverse events, inefficacy.<BR/>Mental state: PANSS total score.<BR/>Adverse effects/event: at least one adverse effect, QTc prolongation, cholesterol, extrapyramidal effects (akathisia, parkinsonism, AIMS, BAS, SAS), glucose, sexual dysfunction, sedation, weight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Diagnostic tool<BR/>DSM III-R and DSM-IV - Diagnostic Statistical Manual version 3 Revised and version 4.<BR/>ICD 10 - The International Statistical Classification of Diseases and Related Health Problems.<BR/>
</P>
<P>Rating Scales:</P>
<P>Global rating scales:<BR/>CGI - Clinical Global Impressions.<BR/>CGI-S - Clinical Global Impression-Severity.<BR/>CGI-I - Clinical Global Impression-Improvement.</P>
<P>Mental state:<BR/>BPRS - Brief Psychiatric Rating Scale.<BR/>MADRS - Montgomery-Asberg Depression Rating Scale.<BR/>MMSE - Wiing Mini Mental State Examination.<BR/>PANSS - Positive and Negative Syndrome Scale.<BR/>SANS - Scale for the Assessment of Negative Symptoms.<BR/>SAPS - Scale for the Assessment of Positive Symptoms.<BR/>
</P>
<P>Side effects:<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>BAS - Barnes Akathisia Scale.<BR/>ESRS - Extrapyramidal Syndrome Rating Scale.<BR/>SAS - Simpson-Angus Index - for neurological side effects.<BR/>UKU - Udvalg for kliniske ndersogelser Side Effect Rating Scale -side effect rating scale.</P>
<P>Quality of Life:<BR/>QLS - Quality of Life Scale.<BR/>SWN -Subjective Well-being List.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-02-18 13:17:18 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-02-17 13:06:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nielsen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-17 13:06:58 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia - also on clozapine.<BR/>Interventions: sertindole vs placebo augmentation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-12-22 13:28:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perro-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-12-22 13:28:35 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: open-label.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-16 12:01:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Potkin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-16 12:01:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: hospitalised patients with schizophrenia.<BR/>Interventions: sertindole 24mg/day vs sertindole 20mg/day vs haloperidol, inappropriate intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-02-17 12:46:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zurich-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-02-17 12:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-02-18 13:20:16 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-02-18 13:18:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheung-2005">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 12:12:22 +0000" MODIFIED_BY="[Empty name]">
<P>Sertindole versus risperidone safety outcome study.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 11:41:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: open label.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 12:09:40 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N estimate=30.<BR/>Age: over 18 years.<BR/>Sex: both.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 12:12:49 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: dose unknown.</P>
<P>2. Risperidone: dose unknown.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-18 13:17:54 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome - all causes mortality, cardiac events.<BR/>Secondary outcomes - fatal events, hospitalisations, treatment duration.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-17 11:42:27 +0000" MODIFIED_BY="[Empty name]">
<P>April 2004.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 12:13:59 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Hung Kin Cheung<BR/>Team B<BR/>Department of Psychiatry<BR/>Castle Peak Hospital<BR/>Hong Kong, China<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-18 13:18:52 +0000" MODIFIED_BY="[Empty name]">
<P>Estimated study completion date: December 2006.</P>
<P>Sponsor: H. Lundbeck A/S.<BR/>Key Objectives: To compare the safety of sertindole with that of an active control under normal conditions of use.<BR/>Status: Publication process ongoing.<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-17 13:27:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundbeck-2006a">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 13:24:48 +0000" MODIFIED_BY="[Empty name]">
<P>A prospective randomised double-blind parallel-group active-referenced trial of sertindole in schizophrenia<BR/>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 13:25:02 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 13:25:18 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 13:25:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: no further details.<BR/>2. Active control: no further details.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-17 13:26:16 +0000" MODIFIED_BY="[Empty name]">
<P>Efficacy safety and tolerability.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-17 13:26:27 +0000" MODIFIED_BY="[Empty name]">
<P>October 2008.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 13:27:15 +0000" MODIFIED_BY="[Empty name]">
<P>No contact information.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-17 13:27:11 +0000" MODIFIED_BY="[Empty name]">
<P>Status: publication process ongoing.<BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-18 13:18:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundbeck-2006b">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 13:18:00 +0000" MODIFIED_BY="[Empty name]">
<P>Exploratory cognition study of sertindole in patients with schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 13:21:31 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blinding: double.<BR/>Duration: 12 weeks.<BR/>Setting: Korea, Taiwan.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 13:19:04 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N estimate=96.<BR/>Age: over 18 years-65.<BR/>Sex: both.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 13:19:18 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: dose 12 to 20 mg daily.<BR/>2. Olanzapine: dose 10 to 20 mg daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-17 13:20:35 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome - global cognitive composite score.<BR/>Secondary outcomes - cognitive sub-scores.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-17 13:20:48 +0000" MODIFIED_BY="[Empty name]">
<P>October 2006.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 13:21:49 +0000" MODIFIED_BY="[Empty name]">
<P>Study Director<BR/>LundbeckClinicalTrials@lundbeck.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-18 13:18:48 +0000" MODIFIED_BY="[Empty name]">
<P>Estimated study completion date: April 2008.</P>
<P>Sponsor: H. Lundbeck A/S.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-17 13:14:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundbeck-2007a">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 13:09:46 +0000" MODIFIED_BY="[Empty name]">
<P>Study on metabolic parameters of sertindole in patients with schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 13:09:58 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blinding: double.<BR/>Duration: 12 weeks.<BR/>Setting: China.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 13:10:28 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N estimate=250.<BR/>Age: over 18 years-65.<BR/>Sex: both.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 13:11:44 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: dose 12 to 20 mg daily.<BR/>2. Olanzapine: dose 10 to 20 mg daily.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-17 13:12:35 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome - changes from baseline for each component of metabolic syndrome.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-17 13:12:47 +0000" MODIFIED_BY="[Empty name]">
<P>March 2007.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 13:14:31 +0000" MODIFIED_BY="[Empty name]">
<P>Study Director<BR/>LundbeckClinicalTrials@lundbeck.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-17 13:13:55 +0000" MODIFIED_BY="[Empty name]">
<P>Estimated study completion date: April 2008.</P>
<P>Sponsor: H. Lundbeck A/S.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-17 12:41:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundbeck-2008">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 12:33:27 +0000" MODIFIED_BY="[Empty name]">
<P>Efficacy study exploring the effects on cognition of sertindole versus comparator in patients with schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 12:41:34 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blinding: double.<BR/>Duration: 12 weeks.<BR/>Setting: USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 12:34:55 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N estimate=260.<BR/>Age: over 18 years-55.<BR/>Sex: both.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 12:37:22 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: once daily oral dose, day 1-20 4-16 mg/day, day 21-84 12, 16 or 20 mg/day.<BR/>2. Quetiapine: twice daily oral dose, day 1-20 50-500 mg/day, day 21-84 400, 500 or 600 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-17 12:39:40 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome - neurocognitive effect of treatment based on the overall composite score on the MCCB.<BR/>Secondary outcomes - domain specific scores on MCCB, PANSS total score, PANSS subscale scores, CGI-S, CDSS, GAF, QLS, UPSA total and subscale scores, ECGs.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-17 12:40:04 +0000" MODIFIED_BY="[Empty name]">
<P>March 2008.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 12:41:19 +0000" MODIFIED_BY="[Empty name]">
<P>Study Director<BR/>LundbeckClinicalTrials@lundbeck.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-17 12:40:40 +0000" MODIFIED_BY="[Empty name]">
<P>Estimated study completion date: May 2009.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-17 12:43:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sireling-2003">
<CHAR_STUDY_NAME MODIFIED="2009-02-05 08:58:41 +0000" MODIFIED_BY="[Empty name]">
<P>Sertindole versus risperidone: safety outcome study.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-14 15:08:46 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: random, no further details.<BR/>Blinding: partially blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-05 08:57:46 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 12:43:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: dose unknown.</P>
<P>2. Risperidone: dose unknown.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-01-12 22:24:52 +0000" MODIFIED_BY="[Empty name]">
<P>Not known.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-01-12 22:24:54 +0000" MODIFIED_BY="[Empty name]">
<P>November 2002.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 11:36:02 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Lester Sireling<BR/>Consultant Psychiatrist<BR/>Primary Care Mental Health Team and Early Intervention Service<BR/>6th Floor Premier House<BR/>112 Station Road<BR/>Edgware, Middx<BR/>HA8 7BJ</P>
<P>lester.sireling@beh-mht.nhs.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-17 11:37:06 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Sireling contacted and kindly responded:</P>
<P>"This study was part of a multi-centre study organised by the drug company. It has been completed. For further information please contact the company".</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-18 13:19:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spaniel-2008">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 12:50:52 +0000" MODIFIED_BY="[Empty name]">
<P>ITAREPS Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 12:54:28 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 1 year.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 12:56:18 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N estimate=150.<BR/>Age: over 18 years-60.<BR/>Sex: both.<BR/>Setting: Czech Republic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 12:52:16 +0000" MODIFIED_BY="[Empty name]">
<P>1. Information technology-aided program of relapse prevention (may include dose management of sertindole).<BR/>2. Treatment as usual.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-18 13:19:50 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome - hospitalisations for psychotic relapses.<BR/>Secondary outcomes - EWSQ 10P and 10FM, hospitalisation days, natural course of illness, correlation between baseline CGI and the No. of hospitalisations.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-17 12:54:40 +0000" MODIFIED_BY="[Empty name]">
<P>November 2008.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 12:57:45 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Filip Spaniel<BR/>Prague Psychiatrc Center<BR/>Ustavni<BR/>Czech Republic, 181 03<BR/>
</P>
<P>spaniel@pcp.lf3.cuni.cz</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-18 13:19:58 +0000" MODIFIED_BY="[Empty name]">
<P>Sponsor: Ely Lilly.</P>
<P>Estimated study completion date: November 2009.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-02-18 13:20:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiser-2007">
<CHAR_STUDY_NAME MODIFIED="2009-02-17 12:25:54 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of cognitive functions of schizophrenic patients treated with sertindole versus risperidone</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-02-17 12:27:19 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Blinding: open label.<BR/>Duration: 24 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-02-17 12:28:16 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia.<BR/>N estimate=60.<BR/>Age: over 18 years-65.<BR/>Sex: both.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-02-17 12:28:03 +0000" MODIFIED_BY="[Empty name]">
<P>1. Sertindole: dose unknown.</P>
<P>2. Risperidone: dose unknown.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-02-18 13:20:16 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: cognitive functioning.<BR/>Secondary outcome: discontinuation due to all causes, symptomatology and adverse effects.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-02-17 12:30:27 +0000" MODIFIED_BY="[Empty name]">
<P>Unknown.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-02-17 12:29:19 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Mark Weiser<BR/>Shaba Medical Center<BR/>Tel-Aviv University Sackler School of Medicine<BR/>Israel<BR/>
<A HREF="mailto:mweiser%40netvision.net.il?subject=NCT00480844, SHEBA-07-4639-JL-CTIL, Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone">mweiser@netvision.net.il</A>
<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-02-17 12:28:40 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-02-18 10:58:10 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-02-05 17:39:26 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 19:10:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-17 12:03:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Random, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-02-05 17:39:26 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 19:10:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-02 19:14:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>No further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-02-16 09:25:33 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-16 09:25:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Double, identical capsules.<BR/>Whether blinding was successful was not examined - but adverse effects differ substantially.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-05 08:32:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Outcomes such as laboratory measures or death - unlikely to have been much affected by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-02-16 09:24:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Double, no further details.<BR/>Whether blinding was successful was not examined - but adverse effects differ substantially.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-16 09:25:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Outcome measures such as leaving the study early are unlikely to be influenced by lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2009-02-05 17:39:26 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-05 08:34:20 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Data for leaving study early were available but total was high (35.8%). <BR/>Last-observation-carried-forward method used (assumes that participants who discontinue remain stable).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-02-05 08:54:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Data for leaving study early were available but total was high (32.4%).<BR/>Last-observation-carried-forward method used (assumes that participants who discontinue remain stable).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-02-18 10:58:10 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-18 10:58:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Adverse events - only reported if &gt; 5% occurrence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-16 09:24:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Adverse events - only reported if &gt; 10% occurrence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-02-05 17:39:26 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-05 08:35:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azorin-2006">
<DESCRIPTION>
<P>Sponsored by manufacturers of sertindole.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-05 08:57:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kane-2005">
<DESCRIPTION>
<P>Sponsored by manufacturers of sertindole.<BR/>After titration period lower dose limit for risperidone = 6mg/day - rather high and can be associated with extrapyramidal effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-02-05 16:51:15 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-02-05 16:51:15 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-12-14 15:09:58 +0000" MODIFIED_BY="[Empty name]">Suggested design of future study</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Methods</P>
</TH>
<TD>
<P>Allocation: randomised - clearly described generation of sequence and concealment of allocation.<BR/>Blinding: double - described and tested.<BR/>Duration: 6 months minimum.</P>
</TD>
</TR>
<TR>
<TH>
<P>Participants</P>
</TH>
<TD>
<P>Diagnosis: schizophrenia (operational criteria).<BR/>N=2700.*<BR/>Age: any.<BR/>Sex: both.<BR/>History: any.</P>
</TD>
</TR>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TD>
<P>1. Sertindole: dose ~ 12-24 mg/day. N=300.<BR/>2. Amisulpride: dose ~ 400-800 mg/day. N=300.<BR/>3. Aripiprazole: dose ~ 10-30 mg/day. N=300.<BR/>4. Clozapine: dose ~ 300-800 mg/day. N=300.<BR/>5. Olanzapine: dose ~ 10-20 mg/day. N=300.<BR/>6. Quetiapine: dose ~300-800 mg/day. N=300.<BR/>7. Risperidone: dose ~ 4-8 mg/day. N=300.<BR/>8. Ziprasidone: dose ~ 120-160 mg/day. N=300.<BR/>9. Zotepine: dose ~ 100-300 mg/day. N=300.</P>
</TD>
</TR>
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TD>
<P>Leaving study early (any reason, adverse events, inefficacy).<BR/>Service outcomes: hospitalised, time in hospital, attending out patient clinics.<BR/>Global impression: CGI**, relapse, healthy days.<BR/>Mental state: PANSS.<BR/>Adverse events: UKU, ECG.<BR/>Functioning: employment.<BR/>Satisfaction: family, patient.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* power calculation suggested 300/group would allow good chance of showing a 10% difference between groups for primary outcome.<BR/>
<BR/>** Primary outcome<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-02-16 09:48:40 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-02-16 09:48:40 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>SERTINDOLE versus RISPERIDONE</NAME>
<DICH_OUTCOME CHI2="0.46140177239734265" CI_END="1.570414858297621" CI_START="1.0149972859758034" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2625239875060439" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.1960143956381422" LOG_CI_START="0.0064648809809477945" LOG_EFFECT_SIZE="0.10123963830954502" METHOD="MH" MODIFIED="2009-02-16 09:48:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9934685219439187" P_Q="0.0" P_Z="0.036290347736166545" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="942" TOTAL_2="582" WEIGHT="300.0" Z="2.093659224118076">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0394681726448943" CI_END="1.5974121039576483" CI_START="0.9444730589799197" DF="1.0" EFFECT_SIZE="1.228296664603641" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="58" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.20341697085775243" LOG_CI_START="-0.0248104257815671" LOG_EFFECT_SIZE="0.08930327253809266" MODIFIED="2009-02-05 09:00:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8425241269169625" P_Z="0.12507108376143705" STUDIES="2" TAU2="0.0" TOTAL_1="314" TOTAL_2="194" WEIGHT="100.0" Z="1.533831612274297">
<NAME>any reason</NAME>
<DICH_DATA CI_END="1.8712440131315389" CI_START="0.8550875622342352" EFFECT_SIZE="1.2649416909620992" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" LOG_CI_END="0.27213042386916036" LOG_CI_START="-0.06798941059576455" LOG_EFFECT_SIZE="0.10207050663669794" ORDER="1" O_E="0.0" SE="0.1997880743850306" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.03991527466647852" WEIGHT="45.026857162015745"/>
<DICH_DATA CI_END="1.7090488429876314" CI_START="0.8412741631205702" EFFECT_SIZE="1.1990740740740742" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="30" LOG_CI_END="0.23275447462061527" LOG_CI_START="-0.07506244875997332" LOG_EFFECT_SIZE="0.07884601293032097" ORDER="2" O_E="0.0" SE="0.18081318451210268" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" VAR="0.03269340769340769" WEIGHT="54.97314283798425"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.23329092678358376" CI_END="2.570657155860329" CI_START="0.7380573977413201" DF="1.0" EFFECT_SIZE="1.3774224228388972" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.41004415939411404" LOG_CI_START="-0.1319098623598666" LOG_EFFECT_SIZE="0.13906714851712376" MODIFIED="2009-02-16 09:48:40 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.629094343195289" P_Z="0.31447997517919635" STUDIES="2" TAU2="0.0" TOTAL_1="314" TOTAL_2="194" WEIGHT="99.99999999999999" Z="1.0058661494719072">
<NAME>adverse events</NAME>
<DICH_DATA CI_END="2.73621187056407" CI_START="0.5358652719512164" EFFECT_SIZE="1.2108843537414966" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4371497226732013" LOG_CI_START="-0.2709443875517655" LOG_EFFECT_SIZE="0.08310266756071788" ORDER="3" O_E="0.0" SE="0.415937985468521" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.17300440775561157" WEIGHT="58.57913073978514"/>
<DICH_DATA CI_END="4.357666271132819" CI_START="0.626866357529927" EFFECT_SIZE="1.6527777777777777" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.6392539670402824" LOG_CI_START="-0.20282503711775765" LOG_EFFECT_SIZE="0.2182144649612623" ORDER="4" O_E="0.0" SE="0.49464137540072967" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" VAR="0.24467009025832556" WEIGHT="41.42086926021484"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.039116387082088824" CI_END="2.1831062301750714" CI_START="0.7976073290308476" DF="1.0" EFFECT_SIZE="1.3195686906108912" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="19" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.3390748690377492" LOG_CI_START="-0.09821086404565967" LOG_EFFECT_SIZE="0.1204320024960448" MODIFIED="2009-02-05 09:00:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8432183540986844" P_Z="0.28032942773197933" STUDIES="2" TAU2="0.0" TOTAL_1="314" TOTAL_2="194" WEIGHT="100.0" Z="1.0795796415030192">
<NAME>inefficacy</NAME>
<DICH_DATA CI_END="4.278231346758876" CI_START="0.4935186414627485" EFFECT_SIZE="1.453061224489796" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.631264265486606" LOG_CI_START="-0.30669643826992055" LOG_EFFECT_SIZE="0.16228391360834274" ORDER="5" O_E="0.0" SE="0.5509627603669482" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.3035599633111672" WEIGHT="21.73508429597368"/>
<DICH_DATA CI_END="2.269625449010185" CI_START="0.7272174309604327" EFFECT_SIZE="1.2847222222222223" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="14" LOG_CI_END="0.35595419250172283" LOG_CI_START="-0.13833571988619447" LOG_EFFECT_SIZE="0.10880923630776416" ORDER="6" O_E="0.0" SE="0.29034834131119003" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" VAR="0.08430215930215931" WEIGHT="78.26491570402632"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.1966741567738434" CI_END="1.0179740765130205" CI_START="0.7204356391584198" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8563788907133104" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.007736718501036714" LOG_CI_START="-0.14240481125089685" LOG_EFFECT_SIZE="-0.06733404637493007" METHOD="MH" MODIFIED="2009-02-05 09:08:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6574188798365531" P_Q="0.0" P_Z="0.07875226648750698" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="196" TOTAL_2="178" WEIGHT="200.0" Z="1.7579720420627083">
<NAME>Global state: 1. No important change - as defined by original study - short term</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0830039460257226" CI_START="0.7132092130713376" DF="0.0" EFFECT_SIZE="0.8788676761026991" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="62" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.034630039020587845" LOG_CI_START="-0.14678305534497244" LOG_EFFECT_SIZE="-0.056076508162192326" MODIFIED="2009-02-05 09:06:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2256322719990228" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="1.2116869155562833">
<NAME>no significant response</NAME>
<DICH_DATA CI_END="1.0830039460257226" CI_START="0.7132092130713376" EFFECT_SIZE="0.8788676761026991" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="62" LOG_CI_END="0.034630039020587845" LOG_CI_START="-0.14678305534497244" LOG_EFFECT_SIZE="-0.056076508162192326" ORDER="43" O_E="0.0" SE="0.10656294963963012" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.011355662235898345" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.101381816689707" CI_START="0.594897316353948" DF="0.0" EFFECT_SIZE="0.809449866903283" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.04193790220109281" LOG_CI_START="-0.22555799021993414" LOG_EFFECT_SIZE="-0.09181004400942067" MODIFIED="2009-02-05 09:06:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1784963538590425" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="1.3453991988353764">
<NAME>no clinically important change</NAME>
<DICH_DATA CI_END="1.101381816689707" CI_START="0.594897316353948" EFFECT_SIZE="0.809449866903283" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="46" LOG_CI_END="0.04193790220109281" LOG_CI_START="-0.22555799021993414" LOG_EFFECT_SIZE="-0.09181004400942067" ORDER="44" O_E="0.0" SE="0.15712841133413397" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.0246893376483888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0830039460257226" CI_START="0.7132092130713376" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8788676761026991" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="62" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.034630039020587845" LOG_CI_START="-0.14678305534497244" LOG_EFFECT_SIZE="-0.056076508162192326" METHOD="MH" MODIFIED="2009-02-05 09:13:16 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.2256322719990228" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="1.2116869155562833">
<NAME>Mental state: 1a. General - no clinically important change (&lt;50% PANSS total score reduction)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0830039460257226" CI_START="0.7132092130713376" DF="0.0" EFFECT_SIZE="0.8788676761026991" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="62" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.034630039020587845" LOG_CI_START="-0.14678305534497244" LOG_EFFECT_SIZE="-0.056076508162192326" NO="1" P_CHI2="1.0" P_Z="0.2256322719990228" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="1.2116869155562833">
<NAME>Short term</NAME>
<DICH_DATA CI_END="1.0830039460257226" CI_START="0.7132092130713376" EFFECT_SIZE="0.8788676761026991" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="62" LOG_CI_END="0.034630039020587845" LOG_CI_START="-0.14678305534497244" LOG_EFFECT_SIZE="-0.056076508162192326" ORDER="9" O_E="0.0" SE="0.10656294963963012" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.011355662235898345" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="5.586413110462338" CI_END="12.19798147122006" CI_START="-8.238716666411477" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.979632402404291" ESTIMABLE="YES" I2="82.09942622884115" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2009-02-05 09:13:16 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.018100440392379236" P_Q="1.0" P_Z="0.7041607779975712" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="44.74156011307912" TOTALS="SUB" TOTAL_1="306" TOTAL_2="187" UNITS="" WEIGHT="100.0" Z="0.3797098910216206">
<NAME>Mental state: 1b. General - average symptom score (PANSS total, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.586413110462338" CI_END="12.19798147122006" CI_START="-8.238716666411477" DF="1.0" EFFECT_SIZE="1.979632402404291" ESTIMABLE="YES" I2="82.09942622884115" ID="CMP-001.04.01" NO="1" P_CHI2="0.018100440392379236" P_Z="0.7041607779975712" STUDIES="2" TAU2="44.74156011307912" TOTAL_1="306" TOTAL_2="187" WEIGHT="100.0" Z="0.3797098910216206">
<NAME>Short term</NAME>
<CONT_DATA CI_END="3.4200336484279354" CI_START="-10.420033648427935" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-29.3" MEAN_2="-25.8" ORDER="10" SD_1="23.9" SD_2="22.4" SE="3.530694289799342" STUDY_ID="STD-Azorin-2006" TOTAL_1="90" TOTAL_2="82" WEIGHT="47.51309959382864"/>
<CONT_DATA CI_END="12.142099473080464" CI_START="1.737900526919539" EFFECT_SIZE="6.940000000000001" ESTIMABLE="YES" MEAN_1="-12.07" MEAN_2="-19.01" ORDER="11" SD_1="22.31" SD_2="22.31" SE="2.6541811554263033" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" WEIGHT="52.486900406171365"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1200780995769606" CI_END="0.3052791911777286" CI_START="-2.485827189876068" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.09027399934917" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2009-02-05 09:16:16 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7289498576087252" P_Q="0.7289498576087252" P_Z="0.12571523913657662" Q="0.1200780995769606" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="180" TOTAL_2="164" UNITS="" WEIGHT="200.0" Z="1.5312191513087525">
<NAME>Mental state: 2. Specific - average positive and negative symptom scores - short term (PANSS subscore, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.354791523931191" CI_START="-2.9547915239311906" DF="0.0" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2009-02-05 09:15:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.46681731820092953" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="82" WEIGHT="100.0" Z="0.7276672337987689">
<NAME>positive symptoms</NAME>
<CONT_DATA CI_END="1.354791523931191" CI_START="-2.9547915239311906" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="-8.0" MEAN_2="-7.2" ORDER="12" SD_1="7.9" SD_2="6.5" SE="1.0994036323768759" STUDY_ID="STD-Azorin-2006" TOTAL_1="90" TOTAL_2="82" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5315860529659531" CI_START="-3.131586052965953" DF="0.0" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" MODIFIED="2009-02-05 09:16:16 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.16418950620163214" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="82" WEIGHT="100.0" Z="1.3911184657559923">
<NAME>negative symptoms</NAME>
<CONT_DATA CI_END="0.5315860529659531" CI_START="-3.131586052965953" EFFECT_SIZE="-1.2999999999999998" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-6.4" ORDER="48" SD_1="5.8" SD_2="6.4" SE="0.9344998517387411" STUDY_ID="STD-Azorin-2006" TOTAL_1="90" TOTAL_2="82" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2009-02-05 09:18:54 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="59" TOTAL_2="55" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Functioning: Average score - short term (GAF, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.607392988932454" CI_START="-8.407392988932457" EFFECT_SIZE="-2.900000000000002" ESTIMABLE="YES" MEAN_1="-21.1" MEAN_2="-18.2" ORDER="50" SD_1="15.7" SD_2="14.3" SE="2.8099460155258305" STUDY_ID="STD-Azorin-2006" TOTAL_1="59" TOTAL_2="55" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.32980668487222564" CI_END="1.1114112739389208" CI_START="0.9509054576329953" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.02803066397037" ESTIMABLE="YES" EVENTS_1="269" EVENTS_2="161" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.04587479787011747" LOG_CI_START="-0.021862660001970995" LOG_EFFECT_SIZE="0.012006068934073253" METHOD="MH" MODIFIED="2009-02-05 09:22:59 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5657730908385452" P_Q="0.0" P_Z="0.48719046421689527" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="314" TOTAL_2="194" WEIGHT="100.00000000000001" Z="0.6947843466793283">
<NAME>Adverse effects: 1a. General - at least one adverse effect</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.205798210190807" CI_START="0.9309938374930958" EFFECT_SIZE="1.0595238095238095" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="72" LOG_CI_END="0.08127463489105788" LOG_CI_START="-0.03105319372499559" LOG_EFFECT_SIZE="0.02511072058303113" ORDER="15" O_E="0.0" SE="0.065981922560789" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.004353614104817957" WEIGHT="36.36495549568713"/>
<DICH_DATA CI_END="1.1142288735193835" CI_START="0.9163473558413902" EFFECT_SIZE="1.0104556803995006" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="89" LOG_CI_END="0.04697440833960396" LOG_CI_START="-0.03793986898538755" LOG_EFFECT_SIZE="0.0045172696771081915" ORDER="16" O_E="0.0" SE="0.049879066833151825" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" VAR="0.0024879213081460266" WEIGHT="63.63504450431289"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.344341918776597" CI_START="0.012503143994408916" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.8659528874172187" LOG_CI_START="-1.9029807671729937" LOG_EFFECT_SIZE="-0.5185139398778874" METHOD="MH" MODIFIED="2009-02-05 09:23:31 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.4629179306033492" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="0.7340505583858266">
<NAME>Adverse effect/event: 1b. General -death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.344341918776597" CI_START="0.012503143994408916" DF="0.0" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.8659528874172187" LOG_CI_START="-1.9029807671729937" LOG_EFFECT_SIZE="-0.5185139398778874" MODIFIED="2009-02-05 09:23:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.4629179306033492" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="0.7340505583858266">
<NAME>suicide</NAME>
<DICH_DATA CI_END="7.344341918776597" CI_START="0.012503143994408916" EFFECT_SIZE="0.30303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8659528874172187" LOG_CI_START="-1.9029807671729937" LOG_EFFECT_SIZE="-0.5185139398778874" ORDER="22" O_E="0.0" SE="1.6264853351489357" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="2.6454545454545455" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.012885773338567044" CI_END="12.178394695217108" CI_START="1.9429377029258708" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.864346021249901" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.0855900451969958" LOG_CI_START="0.2884588758909458" LOG_EFFECT_SIZE="0.6870244605439708" METHOD="MH" MODIFIED="2009-02-05 09:33:03 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9096218610647774" P_Q="0.0" P_Z="7.288950149527502E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="314" TOTAL_2="194" WEIGHT="100.0" Z="3.37847333290577">
<NAME>Adverse effects: 2. Specific - A. Cardiac - i. QTc prolongation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.934774463447653" CI_START="1.790413306516086" EFFECT_SIZE="4.994897959183674" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="4" LOG_CI_END="1.144099943980589" LOG_CI_START="0.25295329691273477" LOG_EFFECT_SIZE="0.6985266204466618" ORDER="17" O_E="0.0" SE="0.5234639517347042" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.27401450876571265" WEIGHT="80.01312407220907"/>
<DICH_DATA CI_END="34.07927546186233" CI_START="0.5616499981468216" EFFECT_SIZE="4.375" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.5324903529297558" LOG_CI_START="-0.2505342382130917" LOG_EFFECT_SIZE="0.640978057358332" ORDER="18" O_E="0.0" SE="1.0473574709513807" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" VAR="1.0969576719576721" WEIGHT="19.986875927790937"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.0164058226266906E-29" CI_END="22.366593682401692" CI_START="14.83340631759832" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="18.600000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2009-02-05 09:34:00 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.9999999999999964" P_Q="1.0" P_Z="3.717945530716696E-22" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="307" TOTAL_2="188" UNITS="" WEIGHT="99.99999999999999" Z="9.678593760397344">
<NAME>Adverse effects: 2. Specific - A. Cardiac - ii. QTc change from baseline (ms, high=poor))</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="26.93589455418804" CI_START="10.264105445812008" EFFECT_SIZE="18.600000000000023" ESTIMABLE="YES" MEAN_1="429.6" MEAN_2="411.0" ORDER="19" SD_1="29.1" SD_2="27.0" SE="4.253085577051664" STUDY_ID="STD-Azorin-2006" TOTAL_1="91" TOTAL_2="83" WEIGHT="20.417056124145862"/>
<CONT_DATA CI_END="22.822199728923984" CI_START="14.377800271076019" EFFECT_SIZE="18.6" ESTIMABLE="YES" MEAN_1="22.7" MEAN_2="4.1" ORDER="20" SD_1="22.4" SD_2="15.6" SE="2.1542231195206423" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" WEIGHT="79.58294387585413"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.18133560405165206" CI_END="1.4411317214074604" CI_START="0.5214223409462379" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8668553949697491" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.15870367773694635" LOG_CI_START="-0.282810364917191" LOG_EFFECT_SIZE="-0.062053343590122274" METHOD="MH" MODIFIED="2009-02-05 09:52:17 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.6702279531307871" P_Q="0.0" P_Z="0.5816796364902739" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="314" TOTAL_2="194" WEIGHT="100.0" Z="0.5509329570846864">
<NAME>Adverse effects: 2. Specific - B. Central nervous system - i. Sedation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.745970572665432" CI_START="0.3922978040233092" EFFECT_SIZE="1.0379008746355685" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.43869587878657057" LOG_CI_START="-0.4063841229263613" LOG_EFFECT_SIZE="0.01615587793010466" ORDER="36" O_E="0.0" SE="0.49640417621965066" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.24641710616831" WEIGHT="27.295647016402462"/>
<DICH_DATA CI_END="1.470569822725504" CI_START="0.4463576119609224" EFFECT_SIZE="0.8101851851851852" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" LOG_CI_END="0.1674856496553988" LOG_CI_START="-0.35031705458467166" LOG_EFFECT_SIZE="-0.09141570246463643" ORDER="37" O_E="0.0" SE="0.30415987163534164" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" VAR="0.09251322751322752" WEIGHT="72.70435298359753"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.016267484753887" CI_END="0.9390820596943142" CI_START="0.30860046037815947" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5383318269938492" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="50" I2="40.194576762144315" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.027296456173395683" LOG_CI_START="-0.510603430380631" LOG_EFFECT_SIZE="-0.2689499432770134" METHOD="MH" MODIFIED="2009-02-05 09:53:16 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.1706100060459539" P_Q="0.0" P_Z="0.02915712032911368" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1277901923789246" TOTALS="SUB" TOTAL_1="628" TOTAL_2="388" WEIGHT="400.0" Z="2.181355662544235">
<NAME>Adverse effects: 2. Specific - B. Central nervous system - ii. Specific extrapyramidal movements - binary outcomes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9761628406657288" CI_START="0.20340972028640636" DF="0.0" EFFECT_SIZE="0.4456018518518519" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="-0.010477728538730913" LOG_CI_START="-0.6916282974020542" LOG_EFFECT_SIZE="-0.35105301297039254" MODIFIED="2009-02-05 09:39:05 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04335623136041216" STUDIES="1" TAU2="0.0" TOTAL_1="216" TOTAL_2="105" WEIGHT="100.0" Z="2.0202618731844684">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="0.9761628406657288" CI_START="0.20340972028640636" EFFECT_SIZE="0.44560185185185186" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="-0.010477728538730913" LOG_CI_START="-0.6916282974020542" LOG_EFFECT_SIZE="-0.3510530129703926" ORDER="23" O_E="0.0" SE="0.40011121590001086" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" VAR="0.16008898508898511" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1148821045806645" CI_START="0.38349871252912526" DF="0.0" EFFECT_SIZE="0.6538775510204081" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.04722894448089988" LOG_CI_START="-0.41623608971352716" LOG_EFFECT_SIZE="-0.18450357261631364" MODIFIED="2009-02-05 09:39:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.11863997207318908" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="1.5605076140231233">
<NAME>extrapyramidal symptoms</NAME>
<DICH_DATA CI_END="1.1148821045806645" CI_START="0.38349871252912526" EFFECT_SIZE="0.6538775510204081" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.04722894448089988" LOG_CI_START="-0.41623608971352716" LOG_EFFECT_SIZE="-0.18450357261631364" ORDER="24" O_E="0.0" SE="0.27224165527472594" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.07411551886672273" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.6931021150032352" CI_START="0.08523419826260957" DF="0.0" EFFECT_SIZE="0.24305555555555555" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="-0.15920277589993725" LOG_CI_START="-1.0693861195900107" LOG_EFFECT_SIZE="-0.614294447744974" MODIFIED="2009-02-05 09:39:28 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.0081543814558102" STUDIES="1" TAU2="0.0" TOTAL_1="216" TOTAL_2="105" WEIGHT="100.0" Z="2.645609814395909">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="0.6931021150032352" CI_START="0.08523419826260957" EFFECT_SIZE="0.24305555555555555" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="-0.15920277589993725" LOG_CI_START="-1.0693861195900107" LOG_EFFECT_SIZE="-0.614294447744974" ORDER="25" O_E="0.0" SE="0.5346462015637639" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" VAR="0.28584656084656085" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.152044310518624" CI_START="0.3723967707238939" DF="0.0" EFFECT_SIZE="1.5136054421768708" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" ID="CMP-001.12.04" LOG_CI_END="0.7890194548402579" LOG_CI_START="-0.42899409370270947" LOG_EFFECT_SIZE="0.18001268056877429" MODIFIED="2009-02-05 09:39:37 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5623637866320645" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="0.5793340658605401">
<NAME>tremor</NAME>
<DICH_DATA CI_END="6.152044310518624" CI_START="0.3723967707238939" EFFECT_SIZE="1.5136054421768708" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7890194548402579" LOG_CI_START="-0.42899409370270947" LOG_EFFECT_SIZE="0.18001268056877429" ORDER="26" O_E="0.0" SE="0.7154671876784431" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.5118932966445005" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.654316148479637" CI_END="-0.07303754510328228" CI_START="-0.41861257105045" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.24582505807686617" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2009-02-05 09:52:49 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.7530962738772787" P_Q="0.7795786323958489" P_Z="0.005296194411694681" Q="0.4980034645936917" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="805" TOTAL_2="672" UNITS="" WEIGHT="300.0" Z="2.788443748257345">
<NAME>Adverse effects: 2. Specific - B. Central nervous system - ii. Specific extrapyramidal movements - average scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.24096467948469674" CI_END="0.24866598269281381" CI_START="-0.8613874900791606" DF="1.0" EFFECT_SIZE="-0.3063607536931734" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" MODIFIED="2009-02-05 09:45:09 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6235102666743033" P_Z="0.2793189064559509" STUDIES="2" TAU2="0.0" TOTAL_1="298" TOTAL_2="179" WEIGHT="100.0" Z="1.0818506643931938">
<NAME>abnormal involuntary movements (AIMS, high=poor)</NAME>
<CONT_DATA CI_END="0.8934489997029701" CI_START="-1.0934489997029702" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.7" ORDER="27" SD_1="3.0" SD_2="3.3" SE="0.5068710484167919" STUDY_ID="STD-Azorin-2006" TOTAL_1="82" TOTAL_2="74" WEIGHT="31.213082102275518"/>
<CONT_DATA CI_END="0.26920777623222447" CI_START="-1.0692077762322243" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="-1.2" MEAN_2="-0.8" ORDER="28" SD_1="2.87" SD_2="2.87" SE="0.34143881291230344" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" WEIGHT="68.78691789772448"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.39375635106273743" CI_END="-0.030692395481275503" CI_START="-0.41052556100724585" DF="1.0" EFFECT_SIZE="-0.22060897824426068" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.02" MODIFIED="2009-02-05 09:45:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5303318694735955" P_Z="0.022803338511937207" STUDIES="2" TAU2="0.0" TOTAL_1="309" TOTAL_2="191" WEIGHT="100.0" Z="2.2767135219811014">
<NAME>akathisia (Barnes Akathisia Scale, high=poor)</NAME>
<CONT_DATA CI_END="0.19162927376062455" CI_START="-0.9916292737606246" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.5" MEAN_2="-0.1" ORDER="29" SD_1="1.8" SD_2="2.2" SE="0.3018572169832307" STUDY_ID="STD-Azorin-2006" TOTAL_1="93" TOTAL_2="86" WEIGHT="10.304489122130317"/>
<CONT_DATA CI_END="5.291594284713708E-4" CI_START="-0.4005291594284715" EFFECT_SIZE="-0.20000000000000007" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.9" ORDER="30" SD_1="0.86" SD_2="0.86" SE="0.10231267564619546" STUDY_ID="STD-Kane-2005" TOTAL_1="216" TOTAL_2="105" WEIGHT="89.69551087786968"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5215916533385112" CI_END="0.31691705311523893" CI_START="-1.2446421575560318" DF="1.0" EFFECT_SIZE="-0.46386255222039646" ESTIMABLE="YES" I2="34.279345065681156" ID="CMP-001.13.03" MODIFIED="2009-02-05 09:45:33 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21737920405305033" P_Z="0.24425464052254986" STUDIES="2" TAU2="0.10969390421017974" TOTAL_1="198" TOTAL_2="302" WEIGHT="99.99999999999999" Z="1.1644180891968705">
<NAME>extrapyramidal symptoms (Simpson-Angus Scale, high=poor)</NAME>
<CONT_DATA CI_END="0.05861286280845135" CI_START="-1.8586128628084517" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-0.2" ORDER="31" SD_1="3.0" SD_2="3.5" SE="0.48909718258593904" STUDY_ID="STD-Azorin-2006" TOTAL_1="93" TOTAL_2="86" WEIGHT="43.12669513569985"/>
<CONT_DATA CI_END="0.7347609194813115" CI_START="-0.9347609194813112" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="-1.3" ORDER="32" SD_1="3.58" SD_2="3.58" SE="0.4259062544341625" STUDY_ID="STD-Kane-2005" TOTAL_1="105" TOTAL_2="216" WEIGHT="56.87330486430014"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.727093445293737" CI_START="-13.527093445293737" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.8999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2009-02-05 09:55:01 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.2656154382487256" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="1.1132165873878828">
<NAME>Adverse effects: 2. Specific - C. Metabolic - i. Cholesterol change from baseline (mg/dl, increase=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.727093445293737" CI_START="-13.527093445293737" EFFECT_SIZE="-4.8999999999999995" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="8.1" ORDER="21" SD_1="28.4" SD_2="27.3" SE="4.40165916993534" STUDY_ID="STD-Kane-2005" TOTAL_1="116" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.849222125132677" CI_START="-9.849222125132677" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2009-02-05 09:55:07 +0000" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="1.0" P_Q="1.0" P_Z="0.6174952485100753" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="60" UNITS="" WEIGHT="100.0" Z="0.4994033684597566">
<NAME>Adverse effects: 2. Specific - C. Metabolic - ii. Glucose change from baseline (mg/dl, iincrease=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.849222125132677" CI_START="-9.849222125132677" EFFECT_SIZE="-1.9999999999999998" ESTIMABLE="YES" MEAN_1="1.8" MEAN_2="3.8" ORDER="33" SD_1="32.0" SD_2="20.8" SE="4.0047787546334215" STUDY_ID="STD-Kane-2005" TOTAL_1="116" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.411148851369968" CI_START="0.6980841213911967" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2973760932944607" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.382224022212017" LOG_CI_START="-0.15609224033569477" LOG_EFFECT_SIZE="0.1130658909381611" METHOD="MH" MODIFIED="2009-02-05 09:56:08 +0000" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="1.0" P_Q="0.0" P_Z="0.41032224587295507" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="89" WEIGHT="100.0" Z="0.8233266930110188">
<NAME>Adverse effects: 2. Specific - C. Metabolic - iii. Weight - significant gain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.4111488513699677" CI_START="0.6980841213911967" EFFECT_SIZE="1.2973760932944607" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.38222402221201696" LOG_CI_START="-0.15609224033569477" LOG_EFFECT_SIZE="0.1130658909381611" ORDER="38" O_E="0.0" SE="0.31620963732900137" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.0999885347397386" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.1100484002054074" CI_END="1.8637932709397989" CI_START="0.11570760097653043" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9897504359581647" ESTIMABLE="YES" I2="9.913838007878184" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2009-02-05 09:57:00 +0000" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.2920714619232272" P_Q="1.0" P_Z="0.026457615298483644" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.04015104393190663" TOTALS="YES" TOTAL_1="186" TOTAL_2="142" UNITS="" WEIGHT="100.0" Z="2.219428076658945">
<NAME>Adverse effects: 2. Specific - C. Metabolic - iii. Weight - change from baseline (kg)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.6923601252336542" CI_START="-0.492360125233654" EFFECT_SIZE="0.6000000000000001" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="1.5" ORDER="39" SD_1="3.9" SD_2="3.7" SE="0.5573368357021106" STUDY_ID="STD-Azorin-2006" TOTAL_1="97" TOTAL_2="89" WEIGHT="56.69439600464838"/>
<CONT_DATA CI_END="2.7688001567690463" CI_START="0.23119984323095366" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="2.4" ORDER="40" SD_1="4.6" SD_2="3.1" SE="0.6473589141316779" STUDY_ID="STD-Kane-2005" TOTAL_1="89" TOTAL_2="53" WEIGHT="43.305603995351625"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.48290410589422283" CI_END="6.354499329645895" CI_START="1.322367744772479" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.898790255900222" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.8030813382200366" LOG_CI_START="0.12135224737058369" LOG_EFFECT_SIZE="0.46221679279531014" METHOD="MH" MODIFIED="2009-02-05 09:54:25 +0000" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.48710985465802115" P_Q="0.0" P_Z="0.007866728902147378" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="266" TOTAL_2="171" WEIGHT="100.00000000000001" Z="2.657736860838987">
<NAME>Adverse effects: 2. Specific - D. Sexual dysfunction</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="20.164361066320843" CI_START="1.0225472973564975" DF="0.0" EFFECT_SIZE="4.540816326530612" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="1.3045844653831935" LOG_CI_START="0.009683405193679986" LOG_EFFECT_SIZE="0.6571339352884367" MODIFIED="2009-02-05 09:47:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.04667056909185185" STUDIES="1" TAU2="0.0" TOTAL_1="98" TOTAL_2="89" WEIGHT="27.717271790525754" Z="1.9892776147637308">
<NAME>not-specific - sexual dysfunction</NAME>
<DICH_DATA CI_END="20.164361066320843" CI_START="1.0225472973564975" EFFECT_SIZE="4.540816326530612" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.3045844653831935" LOG_CI_START="0.009683405193679986" LOG_EFFECT_SIZE="0.6571339352884367" ORDER="35" O_E="0.0" SE="0.760631292618945" STUDY_ID="STD-Azorin-2006" TOTAL_1="98" TOTAL_2="89" VAR="0.5785599633111671" WEIGHT="27.717271790525754"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.143288210851135" CI_START="0.9695009955354194" DF="0.0" EFFECT_SIZE="2.4404761904761907" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.7884008906160154" LOG_CI_START="-0.01345174062826995" LOG_EFFECT_SIZE="0.38747457499387267" MODIFIED="2009-02-05 09:47:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.05819794363494315" STUDIES="1" TAU2="0.0" TOTAL_1="168" TOTAL_2="82" WEIGHT="72.28272820947426" Z="1.8942039529994177">
<NAME>specific - abnormal ejaculation</NAME>
<DICH_DATA CI_END="6.143288210851135" CI_START="0.9695009955354194" EFFECT_SIZE="2.4404761904761907" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="5" LOG_CI_END="0.7884008906160154" LOG_CI_START="-0.01345174062826995" LOG_EFFECT_SIZE="0.38747457499387267" ORDER="34" O_E="0.0" SE="0.47101220482743283" STUDY_ID="STD-Kane-2005" TOTAL_1="168" TOTAL_2="82" VAR="0.22185249709639954" WEIGHT="72.28272820947426"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-02-18 10:58:11 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-02-18 10:58:11 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAAEACAMAAACQ12/OAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-02-18 10:58:11 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASsAAAEmCAIAAAC1WCE9AAAN1klEQVR42u3dv24k1RLH8ZFICBxs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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-02-03 17:18:52 +0000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-02-03 17:18:52 +0000" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS MODIFIED="2009-02-03 17:18:52 +0000" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>